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Atherosclerosis, or the accumulation of lipids within the arterial wall, is the underlying process 
responsible for the majority of cardiovascular disease (CVD). Inflammation is one of the 
essential forces driving the development and progression of atherosclerosis. Several cells, 
chemokines, and co-stimulatory molecules of the innate and adaptive immune response have 
been associated with atherosclerosis and cardiovascular risk. Another important risk factor 
associated with atherosclerotic CVD risk is psychosocial stress, and it has been widely 
hypothesized psychosocial stress influences CVD through increased inflammation. Within 
atherosclerotic plaque, greater inflammatory content is associated with plaque instability and 
greater likelihood of plaque to result in a cardiovascular event via erosion or rupture.  
 B-mode ultrasound is an imaging technique that allows for the measurement and 
characterization of atherosclerotic plaque in the superficial arteries such as the carotid and 
femoral arteries. The measurement and characterization of plaque in subclinical stages affords us 
the opportunity to better understand the processes contributing to the development of 
atherosclerosis and for the identification of individuals who may be at risk of having a 
cardiovascular event. 
In this dissertation, the associations between the circulating burden of inflammation and 
coagulation with measures of plaque presence, burden, and characteristics in the carotid and 
femoral arteries are evaluated with the intention of better understanding the inflammatory 
Emma Barinas-Mitchell, PhD 
INFLAMMATION AND CHARACTERISTICS OF ATHEROSCLEROTIC PLAQUE 
Natalie Chrisine Suder, DrPH 
University of Pittsburgh, 2017 
ABSTRACT 
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mechanisms contributing to plaque instability. Additionally, we assessed inflammatory burden as 
a potential mediator of the relationship between perceived everyday discrimination, a measure of 
psychosocial stress, with carotid plaque characteristics.  
Overall, we did not find any independent associations between inflammatory and 
coagulation burden with measures of femoral plaque presence, burden, and characteristics among 
healthy older adults. However we did find several associations between inflammatory and 
coagulation burden with various measures of carotid plaque burden and characteristics 
independent of traditional CVD risk factors among women in midlife. We also identified 
inflammatory burden as a partial mediator of the relationship between everyday discrimination 
and carotid plaque height.  
The findings presented in the following chapters have public health significance because 
they highlight important associations between circulating inflammatory and coagulation burden 
with measures of carotid plaque burden and characteristics among women, and suggest that 
increased inflammatory and coagulation burden may serve as mechanisms contributing to the 
progression and complication of atherosclerotic plaque among women at midlife. Furthermore, 
our results suggest that increased inflammatory burden and greater atherosclerotic plaque height 
may be mechanisms through which experiences of discrimination increase cardiovascular risk 
among midlife women.  
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1.0  DISSERTATION OVERVIEW AND OBJECTIVES 
Cardiovascular disease (CVD) is the leading cause of death globally, and the majority of CVD 
morbidity and mortality is attributed to atherosclerotic disease. Atherosclerosis is a chronic 
inflammatory disease occurring throughout the lifetime that results in the accumulation of lipids 
within the arterial wall. A variety of inflammatory cells, chemokines, and co-stimulatory 
molecules of the innate and adaptive immune system are associated with the development and 
progression of atherosclerotic plaque.  
The subclinical measurement of atherosclerotic plaque via various imaging techniques 
has helped shape our understanding of the processes contributing to various manifestations of 
CVD. Subclinical measures of plaque allow for the assessment of atherosclerotic disease 
progression in different stages and for the identification of individuals at risk of cardiovascular 
events or complications. The purpose of this dissertation is to evaluate the associations between 
circulating markers of inflammation and coagulation with measures of carotid and femoral 
plaque presence, burden, and characteristics identified via B-mode ultrasound. The long-term 
goal of this dissertation is to shed light on the potential mechanisms responsible for plaque 
instability, and help identify characteristics that may put individuals at risk of developing plaque 
that is vulnerable to erode or rupture.  
 
 2 
AIM 1: (a) To determine whether there is an underlying structure to seven circulating 
biomarkers of inflammation and coagulation (CRP, IL-6, ICAM-1, fibrinogen, D-Dimer, PTX-3, 
and Lp(a)). (b) To measure the associations between groups of the circulating biomarkers of 
inflammation and coagulation with measures of femoral artery plaque presence, burden and 
characteristics in healthy older adults. 
 
AIM 2: (a) To determine whether there is an underlying structure to six circulating 
biomarkers of inflammation and coagulation (CRP, IL-6, fibrinogen, D-Dimer, PTX-3, Factor 
VII, and Von Willebrand Antigen). (b) To measure the associations between the groups of 
circulating biomarkers of inflammation and coagulation with measures of carotid artery plaque 
presence, burden and characteristics in midlife women.  
 
AIM 3: (a) To measure the association between perceived everyday discrimination and 
carotid artery plaque presence, burden, and characteristics in midlife women. (b) To determine 
whether this hypothesized relationship is mediated by circulating markers of inflammation and 
coagulation.  
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2.0  GENERAL INTRODUCTION 
2.1 EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE 
Cardiovascular disease (CVD), the world’s leading cause of mortality, is responsible for over 
30% of all deaths globally, and it is estimated that the annual costs of CVD are upwards of US 
$860 billion (1, 2). From 2010 to 2030, the annual number of CVD deaths is expected to increase 
from 18.1 million to an estimated 24.2 million globally, with over 75% of all deaths predicted to 
occur in low- and middle-income countries (3). The leading causes of CVD mortality, coronary 
heart disease (CHD) and stroke, are responsible annually for 7.4 million deaths and 6.7 million 
deaths, respectively (1). In the U.S., CVD mortality steadily declined from the mid-1990s 
through the early 2000s, but has experienced a slight increase since 2011 (4). CVD remains the 
leading cause of death in non-Hispanic white and non-Hispanic black Americans, while cancer 
has eclipsed CVD as the leading cause of death in non-Hispanic Asian, Pacific Islander, and 
Hispanic Americans (4, 5). The prevalence of CVD increases with age. In the U.S., 6.3% of men 
and 5.6% of women aged 40-59 years are affected by CHD compared to 19.9% of men and 9.7% 
of women aged 60-79 years. Similarly, stroke prevalence in adults between ages 40-59 is 1.9% in 
men and 2.2% while for those aged 60-79 years the prevalence increases to 6.1% in men and 
5.2% in women.  
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In the U.S., the incidence and prevalence of CVD differs greatly by sex and geographic 
region. Longitudinal studies suggest that women are more likely to have cerebrovascular disease 
as a first event while men are more likely to suffer an event from CHD, and that in general, CVD 
develops approximately ten years later in women compared to men (6, 7). CVD prevalence and 
mortality also vary geographically across the U.S., with the highest burden seen in the 
southeastern states (i.e. the “stroke belt”) (8, 9). Additionally, despite progress leading to a 
steady decrease in CVD mortality rates in the U.S., gender and racial/ethnic disparities in 
cardiovascular health have persisted. Non-Hispanic blacks experience the highest age-adjusted 
CVD mortality rates with an estimated 316.9 deaths per 100,000 persons, followed by non-
Hispanic whites with an estimated 243.5 deaths per 100,000 persons (10). Racial/ethnic 
disparities in CVD burden in the U.S. are predominately attributed to disparities in CVD risk 
factors by poverty status(11). 
 In addition to its role as the leading cause of death worldwide, CVD also contributes 
tremendously to global morbidity. According to the World Health Organization (WHO), CHD 
and cerebrovascular disease (stroke) are the fourth and sixth leading causes of disability-adjusted 
life years (DALYs) lost in the world, contributing to 62.5 million and 46.6 million DALYs lost, 
respectively (12). Peripheral artery disease (PAD), the third leading cause of cardiovascular 
morbidity, is estimated to affect over 202 million people (13). The prevalence of PAD in U.S. 
adults increases steeply with age such that the prevalence in men and women under 60 is less 
than 5%, but in men and women 80 years or older the prevalence increases to 26% and 20%, 
respectively (14). Individuals diagnosed with PAD experience reduced functionality and 
mobility, and have a three times greater risk of mortality due to cardiovascular event such as 
myocardial infarction (MI) or stroke (13). The global prevalence of PAD has increased greatly 
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over the last decade by 13.1% in high income countries and 28.7% in low and middle income 
countries. Consequently, morbidity caused by PAD has steeply increased during the last 20 
years, particularly in women (14).  
Although CVD represents various diseases affecting the heart and blood vessels, 
atherosclerosis is the underlying disease process responsible for the majority of CVD 
manifestations including CHD, cerebrovascular disease, and PAD (5). Therefore, the majority of 
the global burden of CVD morbidity and mortality can be attributed to atherosclerotic CVD. 
2.1.1 Traditional Risk Factors for Atherosclerotic CVD 
 In addition to age, sex, and race/ethnicity described above, several important modifiable 
and non-modifiable risk factors for atherosclerotic CVD have been identified. Traditional risk 
factors for atherosclerotic CVD include high total or low-density lipoprotein (LDL) cholesterol, 
low high-density lipoprotein (HDL) cholesterol, diabetes, cigarette smoking, and high systolic 
blood pressure (SBP) (15). Each of these factors is included in the Framingham Risk Score, 
which is commonly used in order to assess one’s 10-year risk of a coronary event (16). While 
individuals with atherosclerotic disease in one location within the vasculature are more likely to 
have atherosclerosis in another location within the vasculature (17, 18), evidence suggests the 
relative importance of traditional CVD risk factors may vary slightly by disease location. For 
example, individuals with PAD, which results from atherosclerotic disease in the femoral artery, 
are often diabetic, smoke tobacco, and have a heightened inflammatory state compared to those 
with stable angina (19). Alternatively, high SBP is considered the most important modifiable risk 
factor for cerebrovascular disease which results from atherosclerotic disease in the carotid artery 
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(20). Additional risk factors associated with atherosclerotic CVD include but are not limited to: 
family history, obesity, physical inactivity, fasting glucose, and metabolic syndrome (21).  
2.2 ATHEROSCLEROSIS AND PLAQUE 
Atherosclerosis is a chronic inflammatory disease that occurs throughout the lifetime, which 
results in the hardening and thickening of arteries due to the buildup of plaque (lipids, immune 
cells, calcium, and other substances) within the arterial wall (13, 22, 23). While atherosclerotic 
processes are initiated at a young age, it typically remains clinically silent throughout the 
majority of its progression. For example, initial lipid accumulation in the intimal layer of the 
vascular wall takes place in the first decade of life, but CVD events do not usually occur until 
middle-age (24). The progression of plaque can eventually lead to narrowing or a local or distal 
blockage of an affected artery resulting in symptoms such as angina, silent cerebral infarcts, and 
claudication, or serious clinical events such as myocardial infarction (MI), ischemic stroke, and 
acute limb ischemia. 
2.2.1 The Role of Inflammation 
 Atherosclerotic plaque development is a multi-step process that is partially driven by 
inflammation. A variety of inflammatory cells, chemokines, and co-stimulatory molecules 
employed by both the innate and adaptive immune response are involved in plaque development 
and progression (22). Atherosclerotic plaque development is initiated following injury to the 
vascular endothelium that triggers an inflammatory response and allows for lipoprotein 
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penetration of the endothelium (22, 25). Once injury occurs, local macrophages release pro-
inflammatory cytokines, including tumor necrosis factor alpha (TNF-α) and interleukin-1 (IL-1), 
resulting in the recruitment of leukocytes to the site of inflammation and the expression of 
cellular adhesion molecules along the vascular endothelium (25). Intracellular adhesion molecule 
1 (ICAM-1) expressed on the leukocytes, and ICAM-1 and vascular cell adhesion protein 1 
(VCAM-1) expressed on the vascular endothelium allow for diapedesis, the transendothelial 
migration of leukocytes from the circulation to the site of tissue damage, to occur (Figure 2.1) 
(23, 26).  
Obtained from Libby, Nature, 2002. 
Activation of the vascular endothelium and monocyte-endothelial cell interactions allow for 
lipids to also migrate through the vascular endothelium (27). It is not clear precisely why this 
initial injury to the vascular endothelium occurs; however, branches and bifurcations throughout 
the vasculature are especially prone to atherosclerotic plaque development. Turbulent blood flow 
and altered shear stress caused by recirculation are common in the area surrounding bifurcations 
in the vasculature (Figure 2), and these phenomena have been associated with endothelial 
Relevant Acronyms: 
CCR2 = Chemokine receptor type 2 
M-CSF = Macrophage colony-stimulating factor 
MCP-1= Monocyte chemoattractant protein-1 
ROS = Reactive oxygen species 
VCAM-1 = Vascular cell adhesion molecule-1 
Figure 2.1 Mononuclear Phagocytes in Atherogenesis 
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changes, at the gene expression, cellular, and molecular level, that precede plaque initiation and 
development (28).  
Obtained from Kanwar, Nanomedicine, 2002. 
Once lipids have crossed the vascular endothelium and begun accumulating within the 
intima of the vessel wall, macrophages internalize the lipids utilizing receptor-mediated 
endocytosis and micropinocytosis (29). Foam cells are formed when the uptake of lipids by 
macrophages results in an imbalance in the amount of cholesterol retained and released by the 
cell.  Activated macrophages and T cells secrete interleukin 6 (IL-6) in order to recruit additional 
lymphocytes and neutrophils to the developing plaque (22). The pro-inflammatory state also 
results in the migration of smooth muscle cells from the media to the intima of the vascular wall 
(23, 26). Here, smooth muscle cells become activated and proliferate, resulting in further 
inflammation. IL-6 also signals the production and release of C-reactive protein (CRP), an acute 
phase reactant, by the liver. 
Figure 2.2 Atherogenesis Surrounding the Bifurcation 
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In addition to promoting the expansion of plaque lesions, inflammation also contributes 
to the weakening of the fibrous tissue “capping” plaques, which makes the plaque more 
vulnerable to erosion or rupture (30). Specifically, interferon gamma (IFN-γ) secreted by T cells 
disrupts collagen synthesis, and matrix metalloproteinases (MMPs) secreted by T cells and 
macrophages break down collagen within plaque (22). Additionally, neutrophils are rich in tissue 
proteases such as lipocalin, which has been identified in hemorrhaged plaques via histology (31). 
Plaques may fuse together as they expand over time, further increasing the likelihood of 
complications (32).   
2.2.2 Overview of Inflammatory and Coagulation Markers Assessed 
 IL-6 is a pro-inflammatory cytokine that is secreted by T cells and macrophages in 
response to infection or tissue damage in order to activate lymphocytes and increase antibody 
production (33). IL-6 also induces the production of acute-phase proteins by the liver. IL-6 is 
associated with higher odds of PAD and incidence of PAD in cross-sectional and prospective 
cohort studies of older adults (34, 35). Elevated serum IL-6 is independently associated with the 
presence of symptomatic plaques in the carotid artery among older adults (36), and greater extent 
of coronary stenosis among those in mid-life (37). It has also been associated with low 
echogenicity and greater complexity of plaques in the carotid and coronary arteries (38, 39).  
CRP is an acute-phase reactant that is synthesized by hepatocytes in response to 
inflammation, specifically, IL-6 secretion by macrophages and adipocytes (33). CRP binds to 
dead or dying cells in order to activate the complement system so that bacteria and the affected 
cells may be cleared by macrophages. CRP found in the blood plasma is a well-established non-
specific marker of inflammation that has been associated with increased CVD risk such that a 
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circulating CRP level greater than 3mg/dL is considered a CVD risk factor (40). Similar to IL-6, 
higher CRP is associated with higher odds of PAD and incidence of PAD over time independent 
of traditional CVD risk factors (41, 42). Additionally, among those with PAD, CRP is associated 
with faster functional decline and increased mortality (43). Elevated CRP is an independent 
predictor of carotid plaque presence and burden in men, but the relationship among women is 
only marginally significant after adjustment for traditional CVD risk factors (44, 45). CRP is 
negatively correlated with echogenicity of carotid plaques assessed via ultrasound; however this 
association is only borderline statistically significant following adjustment for CVD risk factors 
(39).  
Intracellular Adhesion Molecule (ICAM)-1 is a transmembrane protein expressed on 
activated leukocytes and endothelial cells in the vasculature (33). ICAM-1 facilitates 
transendothelial migration of leukocytes across the vascular endothelium so that they may reach 
the site of injury or tissue damage. Increased ICAM-1 expression is induced by the expression of 
inflammatory cytokines including interleukin (IL)-1 and tumor necrosis factor (TNF). Multiple 
studies have reported an association between increased circulating ICAM-1 and PAD in 
hemodialysis patients (46, 47); however, less is known about this relationship in the general 
population.  
Fibrinogen is an acute phase protein synthesized in hepatocytes in response to 
inflammation which aids in thrombogenesis (48). During clot formation fibrinogen is converted 
to fibrin, which polymerizes with platelets in order to form the clot.  Multiple longitudinal 
studies have reported an association between increased circulating fibrinogen levels and incident 
PAD among both healthy adults and diabetic patients (41, 49, 50). Among individuals with PAD, 
circulating fibrinogen is associated with increased risk of coronary and all-cause cardiovascular 
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mortality (51, 52). In longitudinal cohort studies, elevated fibrinogen levels have been associated 
with carotid plaque presence and greater carotid stenosis (53-55); however, the evidence 
regarding the association between fibrinogen and carotid plaque echogenicity remains mixed 
especially in women (53, 55-57).  
D-Dimer is a fibrin degradation product that is present in the blood after a clot has been 
degraded (58), which is measured in order to determine the presence of a thrombus in the 
vasculature. While D-Dimer is not associated with PAD after adjustment for CVD risk factors, it 
is independently associated with reduced functional performance, increased severity of PAD, and 
increased risk of mortality in those with PAD (59-61). The evidence regarding the associations 
with carotid artery plaque are limited. However, one histologic study of individuals undergoing 
carotid endarterectomy found that higher plasma D-dimer levels were cross-sectionally 
associated with lower echogenicity plaques and greater plaque burden among participants (62), 
and another study examining diabetic patients found that participants with higher D-dimer levels 
were more likely to have ulcerated carotid plaques (57).  
PTX-3 is an acute phase protein synthesized in macrophages, dendritic cells, myeloid 
cells, and endothelial cells (33). PTX-3 initiates the classical pathway of the non-specific 
complement response and is a pattern recognition receptor. In addition to its role in 
inflammation, some studies suggest that PTX-3 plays a role in coagulation by initiating the 
expression of Tissue Factor, an activator of the coagulation cascade (63, 64). Few studies have 
examined the association between PTX-3 and PAD (65). In a small study of patients undergoing 
revascularization for PAD, circulating levels of PTX-3 were positively correlated with severity 
of PAD (65). Additionally, in a sample of hemodialysis patients, PTX-3 has been found to be 
cross-sectionally and longitudinally associated with PAD (66, 67). The relationship between 
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PTX-3 and femoral plaque characteristics remains unclear; however, one study found that among 
older adults PTX-3 was associated with increased severity (plaque score) of carotid and femoral 
plaque assessed via B-mode ultrasound (68). 
Lp(a) is a plasma lipoprotein produced in the liver whose primary function remains 
unclear; however it is hypothesized to be a causal genetic risk factor of CVD based on its strong 
association with traditional CVD risk factors and premature coronary heart disease (69, 70). 
Lp(a) was found to be independently associated with symptomatic PAD and lower ABI in the 
population-based KORA study as well as a cohort of  male patients suffering from intermittent 
claudication (71). A recent study of participants in the Multiethnic Study of Atherosclerosis 
similarly found an independent association between Lp(a) and PAD, but when the sample was 
categorized by race/ethnicity the relationship between Lp(a) and PAD remained significant only 
among Hispanic American men and women (72).  
Factor VII is a serine protease found in circulating blood that binds to Tissue Factor in 
order to initiate coagulation, and it is commonly measured as a marker of coagulation activity 
(73). While multiple cohort studies have found significant longitudinal associations between 
elevated Factor VII levels and CVD (74, 75), the results in this area of the literature remain 
mixed (76-78). Investigators from the Cardiovascular Health Study, within which no association 
between circulating Factor VII and CVD was observed, speculate that the variability in Factor 
VII testing between laboratories may contribute to the inconsistent findings (76). Among patients 
undergoing carotid endarterectomy, elevated Factor VII is associated with symptomatic carotid 
plaque (79); however, the relationship between circulating Factor VII with carotid plaque 
presence, burden, and characteristics remains unknown. 
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Von Willebrand Factor Antigen (vwAntigen) allows for the measurement of von 
Willebrand Factor (VWF) protein in the blood plasma. VWF is a protein produced by endothelial 
cells and megakaryocytes that binds to several proteins involved in the coagulation cascade, and 
also binds to platelets in order to facilitate clotting (80). Among patients with transient ischemic 
attack or ischemic stroke, elevated VWF levels are associated with the presence of calcification 
in the carotid artery. (81) 
2.2.3 Plaque Erosion and Rupture 
 As atherosclerosis progresses throughout the vasculature, the majority of plaques will 
remain clinically silent. In fact, plaques may repeatedly rupture or experience erosion of the 
fibrous cap only to heal without causing symptoms or occlusion of the vessel (31). However, 
plaques that have eroded, ruptured, or expanded to an extent that they have caused severe 
narrowing or blockage of the vessel locally or downstream can cause serious symptoms and life-
threatening events (25). While thrombosis is the primary cause of acute cardiovascular events, 
the evidence regarding the proportion of acute events that may be attributed to plaque erosion vs. 
plaque rupture is limited (82). The few studies comparing the prevalence and characteristics of 
erosion and rupture suggest that rupture is a more common cause of acute cardiovascular events 
compared to erosion; however, gender differences may exist with erosion being a more common 
cause of acute events in women (83, 84). Symptoms like chronic angina may occur when 
occlusive plaques limit blood flow, without causing an acute event due to rupture or erosion. 
Although individuals with stable angina are at increased risk of a cardiovascular event compared 
to the general population, their risk is lower than individuals who have previously suffered an 
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acute event (85, 86).  The likelihood that a plaque will result in symptoms or an event may be 
influenced by numerous factors and characteristics.  
The risk of serious complications caused by a specific plaque is heavily dependent upon 
the location of the plaque within the vasculature. First, the occlusion of the coronary or carotid 
arteries by plaque results in more serious health consequences, such as MI and stroke, compared 
to occlusion of the femoral artery. Additionally, plaques are more likely to result in vessel 
occlusion in the carotid or coronary arteries than the larger, lower extremity vessels (87). 
Moreover, characteristics of plaques typically vary based on vascular bed. A histologic study of 
individuals who underwent carotid and femoral endarterectomy found that femoral artery 
plaques contained significantly more calcium and less lipid content compared to carotid artery 
plaques, and that plaques found in the carotid and coronary arteries are of higher American Heart 
Association (AHA) lesion grade than plaques found in the femoral arteries(88). According to an 
autopsy study of individuals with carotid and femoral atherosclerosis, carotid plaques were more 
likely to contain foam cells and lipid core while femoral plaques were dominated by fibrous 
content, suggesting that femoral plaques may be more stable than those found in the carotid (89). 
These differences in characteristics could be due to the fact that the carotid and coronary arteries 
are narrower and experience more turbulent blood flow than the femoral artery making them 
more susceptible to endothelial injury, and that atherosclerosis typically develops later in the 
femoral arteries compared to the carotid and coronary arteries (89, 90).  
There are also numerous features that may indicate how far along a plaque has 
progressed, and how prone it may be to erosion or rupture at a given time. Typically, plaque 
components that are associated with stability of the plaque are thick fibrous cap, high collagen 
content, high smooth muscle content, low macrophage content, and small fatty core (91). In 
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contrast, components that are associated with plaques that are more vulnerable to rupture or to 
erode are thin fibrous cap, lipid-rich necrotic core, intraplaque hemorrhage, greater inflammatory 
burden (i.e. high macrophage content), and neoangiogenesis. However, plaques may contain 
several of the above listed components, and those components may change over time (92). 
Therefore, plaques often cannot simply be identified as “stable” or “vulnerable”. One 
characteristic of plaque that is particularly complicated in terms of interpreting the risk of a 
serious health event is calcification. For many years, calcification has been utilized as a marker 
of progressive atherosclerosis within the general population. However, among those with 
cardiovascular disease, calcification of plaque may be an indicator of the body’s effort to 
stabilize existing plaque (93, 94). Due to the complex and dynamic nature of changes in 
atherosclerotic plaque over time, the mechanisms triggering acute cardiovascular events via 
plaque erosion or rupture are still unclear. This dissertation aims to shed light on the potential 
inflammatory and thrombogenic mechanisms that may influence the likelihood of plaque to 
erode or rupture.  
Epidemiologic studies using histologic specimens and magnetic resonance imaging 
(MRI) in order to study the relationships between specific components of carotid plaque and risk 
of cerebrovascular events have found extremely consistent results. In 2013, Howard et al. found 
that lipid rich necrotic core (LRNC) and inflammatory burden are associated with significantly 
increased odds of a cerebral event in the previous six months in a retrospective histologic study 
of over 1,600 individuals who underwent carotid endarterectomy in the Athero-Express and 
Oxford Plaque Studies (OR = 1.38 and OR=1.32, respectively) (95). Conversely, fibrous content 
and calcification were found to be associated with significantly reduced odds of cerebral event in 
the previous six months (OR = .71 and OR=.70, respectively). Another histologic study of the 
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Athero-Express and Oxford Plaque Study that used immunohistochemical staining in order to 
identify specific plaque components found that participants in the highest quartile of predicted 
stroke risk had greater odds of plaques containing thrombus (OR=1.42), high macrophage 
content (OR=1.41), and high microvessel density (OR=1.49), and less fibrous content (OR=.65) 
compared to individuals in the lowest quartile of predicted stroke risk (96). Using MRI to 
characterize plaque components, Takaya et al. found in 2006 that asymptomatic individuals with 
thin or ruptured cap (HR=17.0), intraplaque hemorrhage (HR=5.2), and lipid rich necrotic core 
(HR=1.6) had a higher hazard of a cerebrovascular event over the mean 38.2-month follow-up 
time (97). Similarly, in 2013 Esposito-Bauer et al. found that lipid-rich necrotic core and 
thin/ruptured fibrous cap identified via MRI are associated with the development of cerebral 
ischemia over 41-month follow-up in 83 asymptomatic individuals with ≥ 50% stenosis of the 
internal carotid artery (ICA) (98). Lastly, a study comparing 41 patients suffering acutely from 
transient ischemic attack (TIA) to 40 asymptomatic patients matched by percent carotid stenosis 
found that symptomatic patients were significantly more likely to have carotid plaques with a 
rupture to the fibrous cap. Symptomatic patients were also more likely to have plaques with 
intraplaque hemorrhage and luminal thrombus; however, these differences were not statistically 
significant (99).  
2.3 MEASURING AND CHARACTERIZING PLAQUE 
Because symptoms and complications of CVD typically present themselves only after the disease 
has developed for many years, the study of subclinical CVD provides valuable insight into the 
pathologic processes that lead to CVD events. Additionally, measurement of subclinical CVD 
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allows for the assessment of an individual’s risk of developing CVD complications, and offers an 
opportunity for prevention.  
The measurement of plaque presence and extent is a direct measure of atherosclerotic 
burden, and is a well-established indicator of CVD risk in longitudinal epidemiologic studies 
(100-102). There are numerous methods that can be utilized to measure plaque presence, some of 
which also allow for the characterization of plaque that is identified (see Table 2.1). There are 
strengths and limitations of each method, and the ideal method of plaque measurement is highly 
dependent upon the population being studied.  Invasive techniques utilized to measure plaque 
include: intravascular ultrasound (IVUS), optical coherence tomography (OCT), intravascular 
magnetic resonance (IVMR), and near infrared spectroscopy (NIRS) (103). These techniques all 
offer high-resolution images of the vessel wall and plaque structure, and allow for several plaque 
components to be identified. However, they are all invasive, relatively expensive, and time-
consuming, making them undesirable for the study of subclinical atherosclerosis in the general 
population.     
There are several noninvasive methods of plaque assessment that also allow for the 
collection of high-resolution images and the characterization of plaque including: computed 
tomography (CT), MRI, positron emission tomography (PET), and single positron emission 
computed tomography (SPECT) (103, 104). While these techniques are valuable methods of 
assessing plaque morphology and specific plaque components, individuals undergoing CT, PET, 
and SPECT are exposed to radiation. Additionally, contraindications and aversion to MRI make 
it  impractical for the study of plaque presence in certain populations (105). Duplex ultrasound is 
another noninvasive method of assessing plaque in the superficial arteries with high temporal 
resolution (103). Ultrasound is quick, inexpensive, and functional making it a desirable method 
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of plaque assessment in large studies. While ultrasound cannot be utilized to visualize plaque in 
the coronary arteries, it can assess plaque in the carotid and femoral arteries both of which are 
associated with atherosclerosis in the coronary arteries (90, 106-108). Reliability of determining 
plaque presence within- and between-sonographers ranges from k=0.72-0.78 (109), and a 
reproducibility study of plaque scoring based on the number and size of lesions found a between-
sonographer intraclass correlation coefficient of 0.86 (110, 111). 
More advanced methods of B-mode ultrasound such as 3D or 4D B-mode ultrasound 
allow for the measurement of plaque volume, identification of surface area deformation and 
temporal resolution (112). Additionally, high-risk plaque components such as intraplaque 
vascularization and ulceration may be assessed via contrast-enhanced ultrasound (113). Although 
traditional 2D B-mode ultrasound does not allow for the visualization of specific plaque 
components, it does allow for crude markers of plaque characteristics, such as echogenicity, to 
be measured. Between sonographer agreement regarding plaque characteristics such as thickness 
and echogenicity range from k=.54-.73 (109). This dissertation focuses on the detection and 
characterization of atherosclerotic plaque using images obtained via 2D B-mode ultrasound of 
the femoral arteries of older adults from the San Diego Population Study and the carotid arteries 
of midlife women in the MS Heart Study.  
2.3.1 Detection and Measuring Plaque Using 2D B-Mode Ultrasound 
 Carotid plaque measured via B-mode ultrasound is a well-established measure of 
subclinical atherosclerosis (Table 2.2) (100-102). In addition to its widespread use in 
epidemiological studies, carotid B-mode ultrasound is also used clinically in order to screen 
individuals who may be at risk of stroke (101). The carotid artery is primarily of interest because 
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the carotid artery supplies the brain with oxygen rich blood. Typically, ultrasound is used to 
assess the common carotid, the bifurcation, and the internal carotid artery. Atherosclerosis in the 
external carotid that supplies the face with blood is not usually measured (Figure 2.3). 
Obtained from: https://www.nhlbi.nih.gov/health/health-topics/topics/catd 
Similar to the carotid, the femoral artery is a superficial artery that may be easily assessed 
via ultrasound for the presence of atherosclerotic plaque. Due to the fact that femoral plaques do 
not directly lead to major acute cardiovascular events like carotid or coronary plaques do, it has 
been less commonly assessed throughout the literature (Table 2.3). However, atherosclerosis in 
the femoral artery can lead to PAD, and can cause symptoms such as numbness and pain in the 
legs (114). And in severe cases where the vessel is occluded, circulation to the leg may be cut off 
resulting in gangrene and amputation. Typically, the bifurcation of the common femoral artery 
into the deep and superficial femoral arteries is assessed for atherosclerosis (Figure 2.4) (115, 
116).    
 
Figure 2.3 Carotid Artery Disease 
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Obtained from: McDermott, JACC, 2008. 
 
2.3.1.1 Measurement of Carotid Plaque 
Carotid plaque presence is first assessed via ultrasound by sonographers who examine 
specific segments of the artery for plaque (101). Sonographers obtain images of the various 
carotid segments of interest, which may be assessed for plaque presence by the sonographer in 
real-time or by a trained ultrasound reader at a later time. The definition used to identify plaque 
via ultrasound in a research setting is not entirely consistent throughout the literature. However, 
the most commonly used definitions are based on the Mannheim consensus and American 
Society of Echocardiography Carotid Intima-Media Thickness Task Force consensus criteria, 
Figure 2.4 Location of Femoral Imaging 
 21 
which define plaque presence as a focal wall thickening that is at least 50% greater than the 
surrounding IMT or as a focal structure that protrudes >1.5mm into the vessel lumen distinct 
from the adjacent boundary (101, 117).  
There is also heterogeneity among studies regarding measures of plaque burden. Some 
measures are based on the number of segments of the carotid containing plaque, while others 
consider the size of plaque in addition to the number of segments containing plaque (106, 118, 
119). Other common measures of plaque burden throughout the literature include percent 
luminal stenosis, area, height, length, and maximum thickness (119-123). Percent luminal 
stenosis is sometimes described categorically as “plaque grade”, which can be determined in 
each segment of the carotid (110, 121). Plaque area is frequently measured, and a great deal of 
evidence suggests that greater plaque area is associated with increased cardiovascular risk (120, 
124-126). For example in the BioImage Study, among those with carotid plaque, greater plaque 
area is associated with a 2.36 times higher hazard of a major adverse cardiac event over 2.5 years 
of follow-up (120). And in the Tromso study, each standard deviation increase in square-root-
transformed plaque area is associated with a higher hazard of ischemic stroke over 10 years of 
follow-up (HR=1.23 and 1.19 in men and women, respectively) (124).  
2.3.1.2  Epidemiologic Studies of Carotid Plaque Presence 
Plaque in the carotid artery is significantly correlated with atherosclerosis in the coronary 
arteries (PPV=91%), and improves risk prediction for CVD event when added to traditional risk 
factors (107, 127). Two retrospective investigations of the Rotterdam Study population have 
demonstrated that carotid plaque presence is associated with significantly higher odds of stroke 
(all subtypes) (OR=2.44) and cerebral infarction (OR=2.70) after six years of follow-up, and 
significantly associated with increased hazard of MI (HR = 1.72) after 10 years of follow-up 
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(100, 102). Multiple prospective studies of asymptomatic individuals have found that carotid 
plaque presence is associated with a significantly increased hazard of composite vascular 
outcomes (stroke, MI, CVD death) over time (120, 128). Additionally, sex differences in the 
risks associated with carotid plaque presence has been documented. Although women are less 
likely than men of the same age to have carotid plaque (129, 130), according to the Tromso 
Study, carotid plaque presence is associated with a 1.56 times higher risk of MI in men and 3.95 
times higher risk of MI in women after five years while adjusting for covariates (125). 
2.3.1.3  Measurement of Femoral Plaque 
Similar to plaque in the carotid artery, femoral plaque may be identified in real-time by a 
sonographer or via images read by a trained ultrasound reader at a later time. Segments of the 
femoral artery that may be assessed for plaque include the common femoral artery (CFA) 
proximal to the bifurcation of the CFA and the superficial femoral artery (SFA), the bifurcation, 
and the SFA distal to the bifurcation. The presence of plaque in these segments is determined 
identically to plaque in the carotid artery, typically using the Mannheim consensus or American 
Society of Echocardiography consensus criteria (117).  
2.3.1.4 Epidemiologic Studies of Femoral Plaque Presence 
Among individuals with PAD, atherosclerotic plaque presence in the femoral artery is 
associated with reduced functional performance (116). Additionally, plaque in the femoral artery 
is associated with the presence of atherosclerosis in other arterial beds (90, 131). Because 
atherosclerosis in the larger, lower extremity vessels typically develops later then atherosclerosis 
in the smaller arteries, individuals with femoral plaque often have plaque in the carotid and 
coronary arteries  (90). For example, an autopsy study conducted by Dalager et al. in 2007 found 
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that among individuals with plaque in the superficial femoral artery, 100% had plaque presence 
in the coronary arteries (90). Femoral plaque presence is also associated with cardiovascular 
events. According to Davidsson et al., plaque in the femoral artery was associated with 
significantly higher odds of a cardiovascular event (OR=1.99) over 10-year follow-up in a 
population-based sample of men (132). Additionally, femoral plaque presence was found to be 
associated with significantly higher odds of coronary death (OR=7.07) in a cross-sectional 
autopsy study, and a significantly higher hazard of a MACE (HR=5.92) over 4-6 years of follow-
up in individuals with systemic lupus erythematosus (90, 115).  
2.3.2 Characterizing Plaque Using 2D B-Mode Ultrasound 
Echogenicity, or the ability to bounce (reflect) an ultrasonic wave, is a frequently utilized 
surrogate marker of plaque components that may be assessed in plaque via 2D B-mode 
ultrasound. Based on histologic studies of plaques that had formerly been assessed via carotid 
ultrasound, predominately echolucent plaques are associated with higher lipid and macrophage 
content compared to echogenic plaques, while echogenic plaques are associated with more 
fibrous content and calcification (Table 2.4) (133-136). There are several measures that can be 
collected in order to assess the echogenicity of a plaque. Most simply, echogenicity can be 
operationalized as a binary variable, in which case a plaque can be categorized as either 
echolucent or echogenic by automated software or the individual reading the plaque image (137, 
138).  
Additionally, echogenicity may be operationalized as an ordinal or continuous measure. 
Gray-Weale Scale, a scoring method first proposed in 1988, can be used by ultrasound image 
readers to subjectively categorize plaque echogenicity into four levels: Type I – predominantly 
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echolucent with a thin fibrous cap, Type II - echolucent with echogenic areas, Type III – 
echogenic with echolucent areas, or Type VI – uniformly echogenic (139). Plaques categorized 
as more echolucent (Types I and II) are associated with unstable characteristics including 
intraplaque hemorrhage and ulceration in histologic studies; however, this subjective scoring 
method is limited by moderate inter-observer agreement (139, 140).   
The most commonly used continuous measure of echogenicity is grey-scale median 
(GSM). B-mode ultrasound allows for the intensity of reflected ultrasound waves to be indicated 
by a corresponding shade of grey within an ultrasound image (141). GSM of a plaque may be 
determined once it has been outlined, and samples of the blood and adventitia have been selected 
by a reader (Figure 2.5). The selection of blood and adventitia portions within the image is 
necessary for normalization, so that images collected from different ultrasound machines under 
various gain settings may be compared (142). Once a plaque has been outlined, automated or 
semi-automated software can determine the median grey-scale value of the identified plaque. 
Because GSM values may be affected by image quality and the angle at which a plaque image is 
obtained, it is important that standardized procedures are utilized when obtaining images 
particularly for longitudinal studies of plaque.  
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Multiple histologic studies have attempted to determine correlations between GSM and 
specific components of plaque. In individuals undergoing carotid endarterectomy (CEA), GSM 
has been significantly negatively correlated with lipid content and necrotic core content, and 
significantly positively correlated with fibrous content (134, 135). Additionally, a histologic 
study of over 100 CEA patients found that individuals with the lowest quartile of GSM values 
had 3.76 higher odds of having unstable plaque (containing hemorrhage, thrombus, 
neovascularity, or cap rupture) (136).   
Other methods of continuously measuring plaque echogenicity exist, such as percent 
white or plaque density; however, these measures are less commonly utilized and have less 
histologic evidence supporting their association with specific plaque characteristics (143, 144). 
Figure 2.5 Plaque in the Right Carotid Bulb 
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Lastly, bright areas of echogenicity accompanied by an acoustic shadow, an area in which 
ultrasound waves are strongly absorbed by solid structure, can be used to determine whether or 
not a plaque is calcified or not (145, 146).  
2.3.2.1 Epidemiologic Studies of Carotid Plaque Characteristics 
Prospective cohort studies have demonstrated the risks associated with echolucent plaque 
in the carotid artery (Table 2.5) (137, 138, 147-150). A 2001 study conducted by Gronholdt et al. 
found that asymptomatic individuals with echolucent plaque in the carotid artery, defined as 
having a plaque with GSM <74, had a statistically significant 3.1 times higher risk of ischemic 
stroke over time compared to those with echogenic (GSM ≥74)  plaque (137). Similarly, in a 
study conducted by Reiter et al. of nearly 600 asymptomatic individuals with carotid plaque, 
individuals with carotid plaque GSM values in the lowest quartile compared to those in the 
highest quartile had a statistically significant 1.71 times higher hazard of a major adverse 
cardiovascular event (MACE) over three years (148). Calcification has also been found to be 
predictive of CVD events, particularly in studies comparing those with calcified plaque to those 
with no plaque. In the CAPE study, elderly adults with calcified plaque in the carotid artery had 
significantly higher rates of CVD events (RR=2.35 CI=1.5-3.8) and overall mortality (RR=2.72, 
CI=1.4-5.2) after 11-year follow-up compared to elderly adults with no plaque (151). This study 
did not compare rates of CVD events among those with calcified and non-calcified plaque. In the 
Atherosclerosis Risk in Communities (ARIC) study, calcification identified via acoustic 
shadowing has been associated with higher risk of stroke compared to those who have plaques 
without acoustic shadowing in women; however, this relationship was not maintained after 
adjustment for CVD risk factors and was not present in men (147).  
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2.3.2.2 Epidemiologic Studies of Femoral Plaque Characteristics 
 Plaque in the femoral arteries may be characterized using B-mode ultrasound identically 
to plaque in the carotid arteries. Echogenicity, GSM, Gray-Weale Scale, and calcification of 
femoral plaque may all be determined using appropriate software or by the image reader. A 
recent prospective study conducted by Schiano et al. found in individuals diagnosed with PAD 
that the presence of echolucent femoral plaques defined by Gray-Weale Scale criteria was 
associated with a significantly higher hazard of a MACE (HR= 7.24, CI=3.23-16.22) compared 
to echogenic plaque after adjusting for possible confounders, and that continuously measured 
GSM of femoral plaques was independently associated with a significantly lower hazard of a 
MACE (HR= 0.96, CI=0.95-0.98) (149). Although literature examining the associations between 
femoral plaque characteristics and cardiovascular events is limited, the results of the Schiano et 
al. suggest that the relationship is consistent to that seen in the carotid artery (Table 2.5).  
2.4 PSYCHOSOCIAL STRESS AND CARDIOVASCUALR DISEASE 
A broad range of psychosocial exposures are associated with increased risk of CVD (152-154). 
These exposures include negative emotional states such as depression, anxiety or hostility (155-
157), as well as acute traumatic life stressors such as abuse or trauma (158-160). Additionally, 
social factors including but not limited to social support (161), loneliness (162), and 
discrimination (163) are associated with cardiovascular risk.  In longitudinal studies, measures of 
psychosocial stress are predictive of incident CHD and MI in those with existing CHD (154). 
Psychosocial distress (including depression, anxiety, and perceived stress) has also been 
longitudinally associated with fatal and non-fatal stroke (164, 165).   
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 The associations of specific psychosocial stressors with measures of subclinical 
atherosclerosis vary greatly depending on the type of stressful exposure and the subclinical 
outcome. This dissertation will focus on one well-established psychosocial risk factor, perceived 
discrimination, and its potential association with atherosclerotic plaque in the carotid artery. 
Additionally, the evidence supporting increased inflammation as a mechanism linking 
psychosocial stress to atherosclerosis will be explored. 
2.4.1 Inflammation as a Mechanism Linking Psychosocial Stress and CVD 
 Although it was initially believed that stress exerted suppressive effects on the immune 
system, current research suggests that under normal conditions stress temporarily shifts 
immunoregulation toward an anti-inflammatory response (166). However, in the case of chronic 
or long-term stress, the dysregulation of the immune system results in increased inflammation, 
which is believed to contribute to atherosclerotic disease development and progression (152, 
153). There are three main mechanisms by which stress results in a heightened inflammatory 
state described in the literature: increased susceptibility to secondary infection, decreased anti-
inflammatory feedback, and local effects of stress hormones (153).  
 First, stress alters the modulation of the immune system from a Th1 cell to a Th2 cell-
driven response, increasing one’s susceptibility to secondary viral or bacterial infections (166). 
Th1 and Th2 cells are variations of T Helper cells which serve different functions in the immune 
response. Th1 cells initiate the response to intracellular pathogens (i.e. viruses, intracellular 
bacteria) via the secretion of inflammatory cytokines, while Th2 cells initiate B cell activation 
for the response to extracellular pathogens (i.e. parasites, extracellular bacteria) (167). Evidence 
suggests that Th1 cells play a role in plaque development via the secretion of the inflammatory 
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cytokines such as interferon gamma (IFN-γ), and they are commonly found in plaque lesions 
(168). Th2 cells are rarely found within plaque lesions (166, 168).  Based on mouse models, Th2 
cells are hypothesized to counter the atherogenic effects of Th1 cells via the downregulation of 
IFN- γ; however, this are of research is limited to animal models and remains controversial 
(169). When the immune system is chronically shifted from a Th1 to a Th2 cell-driven response 
due to stress, it increases the susceptibility of an individual to common viral or bacterial 
infections (153). This susceptibility can result in infections which ultimately lead to 
inflammation.  
Additionally, decreased anti-inflammatory feedback due to the exhaustion of the 
hypothalamus and adrenal medulla contributes to the heightened inflammatory state under 
chronically stressful conditions. Typically, stress response results in the release of 
glucocorticoids (i.e. cortisol) via the activation of the hypothalamic-pituitary-adrenal (HPA) axis, 
and the release of catelcholamines (i.e. epinephrine) via stimulation of the adrenal medulla by the 
autonomic nervous system (ANS) (152, 153). Both glucocorticoids and catecholamines inhibit 
pro-inflammatory cytokines by mediating the shift in immune response from a Th1 to Th2 cell-
driven response (170). However, under chronically stressful conditions evidence suggests that 
the chronic activation of the HPA axis and the ANS result in increased inflammation via both the 
exhaustion of the hypothalamus and adrenal medulla as well as resistance to the anti-
inflammatory signaling of glucocorticoids and cathelcholamines on a cellular level (153) (Figure 
2.5). Therefore, there is reduced anti-inflammatory feedback occurring during chronic or long-
term stress, which allows for Th1 cells to dominate the immune response.  
Lastly, stress hormones like catelcholamines have direct pro-inflammatory effects locally 
upon release by the adrenal medulla. Catelcholamines induce the production of IL-6 by adipose 
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cells (170).  IL-6, a potent pro-inflammatory cytokine, triggers the acute phase inflammatory 
response including the production of CRP by hepatocytes (171).  
Additionally, the results of a limited number of studies suggest that specific autoimmune 
diseases may be exacerbated by the effects of chronic stress via dysregulation of Th1 and Th2 
cells and chronic HPA activation (172-174). These studies suggest that individuals with 
autoimmune diseases such as rheumatoid arthritis and multiple sclerosis may be at an even 
greater risk of developing a heightened inflammatory state under stressful conditions compared 
to the general population. 
 
Obtained from: Miller et al. Biological Psychiatry. 2009. 
 Figure 2.6 Stress Induced Activation of Inflammatory Response 
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2.4.2 Perceived Discrimination as a Psychosocial Risk Factor for CVD 
 Discrimination, defined as the unjust or prejudicial treatment of different categories of 
people, is an unpredictable and uncontrollable stressful experience that has been linked to a 
broad range of negative health outcomes and behaviors (175). In order to assess the health effects 
of discrimination in epidemiologic studies, questionnaires are typically utilized to measure 
perceived discrimination via self-report. Due to the well-documented racial/ethnic disparities in 
CVD across the U.S., perceived discrimination has gained attention over the last two decades as 
a potential risk factor contributing to the disproportionate effect of CVD on the African 
American population (176).  Perceived discrimination is associated with numerous lifestyle and 
risk factors causally implicated in CVD including smoking (177), physical inactivity (178), 
alcohol and substance abuse (179, 180), high blood pressure (181, 182), poor sleep (176), and 
depression (183, 184). In 2015, Everson-Rose et al. first reported that perceived discrimination 
was longitudinally associated with increased hazard of an incident cardiovascular event 
(HR=1.05, 95% CI = 1.01-1.60) after adjustment for CVD risk factors, chronic stress, and 
depressive symptoms in the Multi-Ethnic Study of Atherosclerosis (MESA) (185). However, 
after stratifying by sex, the association was only seen in male participants. In addition to 
providing evidence of the harmful effects of perceived discrimination on physical health and 
health behaviors, these studies have somewhat consistently reported that the type and attribution 
of discrimination are of lesser importance compared to the frequency and consistency of the 
perceived discrimination. These results support the idea that long-term or consistent exposure to 
discrimination may result in chronic stress that negatively impacts cardiovascular health; 
however, additional studies investigating the mechanisms through which perceived 
discrimination may influence physical health are needed. 
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 There are three main pathways through which perceived discrimination is hypothesized 
to affect mental and physical health outcomes such as CVD (Figure 2.5) (175). First, perceived 
discrimination may exhibit direct negative effects on physical and mental health (Path A). 
Perceived discrimination may also result in chronic heightened stress response such as those 
described in the previous section, which may result in chronic systemic inflammation (Path B). 
Lastly, negative health behaviors may increase among those who perceive that they are 
discriminated against as a method of coping with this stressful experience (Path C).  
 
 
 
 
 
 
 
 
 
 
 
Obtained from: Pascoe and Richman. Psychological Bulletin. 2009. 
 
 
 
Figure 2.7 Hypothesized Pathways by which Perceived Discrimination Influences Health Outcomes 
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There are multiple validated questionnaires that are commonly utilized to measure the 
frequency and type of perceived discriminatory experiences. These questionnaires may focus on 
major experiences like being denied housing or a bank loan as well as more minor experiences 
like feeling as though you receive poor service at restaurants or stores. The Everyday 
Discrimination Scale (EDS) is one of the most widely utilized measures of perceived 
discrimination (186). The EDS is a brief questionnaire that has been validated across 
racial/ethnic groups for the measure of “chronic or episodic, but generally minor” experiences of 
perceived discrimination (To be added in appendix) (187). For example, the EDS includes items 
intended to measure experiences such as being treated with less respect than other people, being 
treated as though you are dishonest, and being treated as though you are not smart (186). Each of 
the 9-items on the EDS are then rated on a 4-point Likert-type frequency scale ranging from 
“never” to “often”. The EDS also includes an item which allows participants to identify the most 
important characteristic to which they attribute their experienced discrimination including race, 
ethnicity, gender, age, income level, language, physical appearance, sexual orientation, or other. 
Overall, the majority of research regarding the role of perceived discrimination in CVD 
development has focused on perceived racial discrimination in African American populations; 
however, evidence suggests that self-reported discriminatory experiences may be related to 
cardiovascular health in various populations (188-190).  
2.4.2.1 Epidemiologic Studies of Perceived Everyday Discrimination and Subclinical CVD 
The number of studies aimed at examining the hypothesized association between 
everyday discrimination and subclinical CVD has increased greatly in recent years. Most of these 
studies have focused on the effects of everyday discrimination on blood pressure (181, 191-195), 
but more recently, studies have begun to incorporate measures of subclinical atherosclerosis 
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including coronary artery calcium (CAC) (196, 197), intima-media thickness (IMT) (188, 198), 
and adventitial diameter (AD) (188). Only one study conducted in the Study of Women’s Health 
Across the Nation (SWAN) has specifically examined the association of EDS with plaque (198). 
This study was conducted in a limited sample of 334 participants from the Pittsburgh site, and 
found only a marginal association between EDS score and carotid plaque index among African 
American participants in unadjusted models.  
The results of the remaining studies focusing on subclinical outcomes are mixed (See 
Table 2.6). Of the six studies that have examined the association between the EDS and blood 
pressure, the three conducted in midlife or older adults found no statistically significant 
association between the EDS and blood pressure even before adjustment for covariates (191-
193). Conversely, three studies conducted among children and young adults have found 
significant associations between EDS score and SPB after adjustment for demographics, physical 
activity, and BMI (181, 194, 195). In one of these studies conducted by Klimentidis et al., EDS 
score was found to be significantly associated with SBP among African American children 
(β=0.20, p=0.041) (181). The two studies focusing on CAC as a subclinical outcome have 
included only African American participants, and have found mixed results. Lewis et al. reported 
that chronic discrimination measured by the EDS was associated with higher odds of CAC 
(OR=2.6 95%CI=1.0-6.47) in SWAN participants after adjustment for covariates (196), while 
Everage et al. has shown that EDS score was associated with lower odds of CAC (OR=0.93 
95%CI=0.87-0.99) among CARDIA participants after adjustment for covariates (197). 
Additionally, two studies among SWAN participants have examined the relationship between 
EDS and cIMT. Among SWAN participants from the Pittsburgh site, Troxel et al. found only 
marginal associations between EDS score and cIMT before adjusting for covariates in their 
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cross-sectional analysis (198).  However, a recent study conducted by Peterson et al. in the 
complete SWAN cohort found that among Caucasian women cumulative unfair treatment 
assessed via the EDS over six time-points was associated with increased cIMT (β =0.03 
p=0.009) and adventitial diameter (β =0.02, p=0.013) after adjustment for covariates (188).  
There are two major limitations to the literature examining the associations between 
perceived everyday discrimination and subclinical CVD. First, many of these analyses have been 
conducted in the same cohort study participants. Although the samples in which these analyses 
have been conducted consist of participants enrolled in reputable cohort studies, it is possible 
that these cohorts are not representative of the entire general population. Therefore, similar 
studies are necessary in samples consisting of participants in various age, sex, and racial/ethnic 
groups. Additionally, several of the analyses described above do not account for depression or 
negative affect. Depression is highly correlated with both perceived discrimination and CVD, so 
it is important to take into account measures of depression and negative affect in these analyses 
as they may confound the hypothesized relationship between perceived discrimination and 
subclinical CVD (183, 184, 199). Lastly, it is worth mentioning that many of the studies were 
conducted only in African American populations or sub-samples of existing cohort studies. The 
literature consistently has suggested that the attribution of discrimination (racial/ethnic vs. other 
types) may not be of importance in regards to the relationship of perceived discrimination and 
subclinical CVD. It may be beneficial for future studies to include a more generalizable study 
population in order to help elucidate the effects of perceived discrimination on different 
measures of clinical and subclinical CVD, and to help determine whether this relationship differs 
by racial/ethnic group.  
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2.5 SUMMARY 
CVD, the leading cause of death globally, is primarily caused by atherosclerosis, a chronic 
disease that results in the accumulation of lipids over time within the arterial wall. Various 
inflammatory cells, chemokines, and co-stimulatory molecules are involved in the initiation of 
atherosclerotic lesion development following arterial injury; however, less is known about the 
potential involvement of these inflammatory cells in the progression, erosion, and rupture of 
atherosclerotic plaque.  
Numerous types of psychosocial stressors are associated with increased CVD risk. One 
specific cause of psychosocial stress, perceived discrimination, has been shown to be associated 
with CVD risk factors, unhealthy behaviors that contribute to CVD, subclinical CVD measures, 
and incident CVD. One mechanism through which psychosocial stress is hypothesized to 
influence CVD risk is increased inflammation due to chronic stress.  
Imaging via B-mode ultrasound allows for the direct identification, measurement, and 
characterization of atherosclerotic plaque in subclinical stages. Assessment of plaque in the 
subclinical phase can help shape our understanding of the processes that contribute to the various 
manifestations of CVD. This dissertation aims to determine whether there is an underlying 
structure to several circulating biomarkers of inflammation and coagulation that have previously 
been associated with CVD risk in order to determine whether groups of these biomarkers are 
associated with measures of carotid and femoral plaque presence, burden, and characteristics 
identified via B-mode ultrasound. Furthermore, this dissertation is intended to measure the 
association between perceived discrimination and carotid plaque, and to determine whether this 
hypothesized relationship is mediated by circulating markers of inflammation and coagulation. 
These analyses may shed light on potential mechanisms responsible for atherosclerotic plaque 
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instability, and may help identify characteristics that put individuals at risk of developing 
atherosclerotic plaque that is vulnerable to erode or rupture.   
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2.6 TABLES 
Table 2.1 Imaging Techniques Used to Visualize Atherosclerotic Plaque 
Technique 
Plaque Characteristics 
Identified Advantages Limitations 
Invasive Imaging Techniques 
Intravascular Ultrasound (IVUS) Plaque distribution, severity, 
cross-sectional area, 
characterization of plaque (lipid 
core and spotty calcification 
High resolution 
images of vessel 
wall and plaque 
structure 
Intra- and interobserver 
subjectivity, invasiveness, 
limited spatial resolution, and 
limited temporal resolution 
Optical Coherence Tomography (OCT) Plaque composition (fibrous, 
fibrofatty, and fatty), thick 
fibrous cap, macrophages, 
neoangiogenesis, and collagen 
formation 
10 times higher 
image resolution 
compared to IVUS 
Requires blood-free imaging 
field, intra- and interobserver 
variation, invasiveness, and 
limited tissue penetration 
Intravascular Magnetic Resonance (IVMR) Early atherosclerosis and more 
advanced plaque formations and 
plaque composition (lipid, 
fibrous, and calcified tissues) 
High resolution of 
plaque structure and 
composition 
Invasiveness and need for 
occlusion balloon 
Near Infrared Spectroscopy (NIRS) Thin fibrous cap, lipid core, and 
macrophages 
High resolution of 
plaque structure 
with reliability 
Invasiveness, limited tissue 
penetration and cardiac 
motion artifact 
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Table 2-1 Continued  
 
Noninvasive Imaging Techniques 
 
   
Computed Tomography (CT) Plaque morphology (eccentric 
pattern, outward remodeling, and 
spotty calcification), coronary 
plaque burden, cap thickness, and 
macrophages  
High spatial and temporal 
resolution, real time, quire 
fast, operator-independent, 
and excellent calcium 
detection 
Radiation exposure, contrast, 
difficult to distinguish 
thrombus, blooming artefacts 
by calcium and 
claustrophobia 
Magnetic Resonance Imaging 
(MRI)  
Plaque morphology, plaque 
composition, lipid-rich necrotic 
core, intraplaque hemorrhage, 
neoangiogenesis, macrophages, 
flow measurement, and 
quantification of stenosis 
No radiation, high soft tissue 
contract, can be repeated 
over time, functional, 
operator independent, with 
or without contrast, and 
many plaque components 
detected 
 
Low resolution, system 
fibrosis due to contrast agent, 
time-consuming metal 
implants contraindicated, 
claustrophobia, cardiac 
motion artefact, and limited 
spatial resolution 
Ultrasound Plaque morphology, intima media 
thickness, flow velocities, and 
neoangiogenesis (contract US) 
High temporal resolution, 
cheap, easy to use, no 
radiation, bedside/large 
availability, fastest, and 
functional 
 
Limited sensitivity and 
specificity, interobserver 
variability, calcium and air 
artefacts, limited spatial 
resolution, and penetration 
Positron Emission Tomography 
(PET) 
Plaque inflammation, 
macrophages, and 
neoangiogenesis 
High sensitivity and specific 
targets are detected 
Limited resolution, radiation 
exposure, expensive, limited 
availability, myocardial 
uptake of FDG, and cardiac 
motion artifact 
Single Positron Emission 
Computed Tomography (SPECT) 
Plaque inflammation, apoptosis, 
lipoprotein accumulation, 
chemotaxis, angiogenesis, 
proteolysis, and thrombogenicity 
High sensitivity, low cost, 
and more spatial resolution 
as compared with PET 
Limited resolution, 
nonspecificity, radiation 
exposure, limited 
availability,  and cardiac 
motion artifact 
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Table 2.2 Carotid Plaque Presence as a Predictor of CVD Outcomes 
Year Author Study N Follow-Up Outcome Measure of Association 
1991 Salonen et al. KIHD 1,277 2.5 yrs MI 
Small plaque  RR=4.15 (1.51-11.47) 
Large plaque  RR=6.71 (1.33-33.91) 
2001 Held et al.  APSIS 558 Med. 3 yrs 
CV death, MI, 
revascularization 
 
CVD death/MI  RR=1.83 (.96-3.51)  
Revascularization RR=1.17 (.70-1.96) 
2002 Hollander et al. Rotterdam 4,217 Avg. 5.2 yrs 
Stroke and cerebral 
infarction 
 
Stroke OR=2.44 (1.42-4.20)   
Cerebral Infarct  OR=2.70 (1.27-5.77) 
2004 Van der Meer et al. Rotterdam 6,389 7-10 yrs MI 
 
Mild plaque  HR=1.33 (.84-2.09) Severe 
Plaque  HR=1.72 (1.72-3.47) 
2005 Rosvall et al.  MDCS 5,163 
 
Med. 7 yrs Stroke   
 
 
HRR=1.75 (1.11-2.75) 
2006 Stork et al.  
 
403 48 months CVD death 
 
 
RR=1.16 (1.03-1.31) 
2007 Cao et al. CHS 5,020 Med. 11 yrs 
 
Composite Vascular 
Outcome (IS, MI, or 
vascular death) 
 
Intermediate Risk  HR=1.41 (1.15-1.72)  
High Risk HR=1.38 (1.14-1.67) 
2007 Johnsen et al. Tromso 6,226 Avg. 5.4 yrs MI 
 
Men RR=1.56 (1.04-2.36)  
Women RR=3.95 (2.16-7.19) 
2007 Prabhakaran et al. 
Northern 
Manhattan  1,118 Avg. 2.6 yrs 
 
Composite Vascular 
Outcome (IS, MI, or 
vascular death) HR=2.6 (CI=1.3-5.3) 
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2009 
 
Cournot et al. 
 
 
2,561 
 
Avg. 6 yrs 
 
CVD death, MI 
 
 
RR=2.81 (1.84-4.29) 
 
 
2010 
 
 
Nambi et al. 
 
 
ARIC 
 
 
13,145 
 
 
Med. 15 yrs 
 
 
CVD death, MI, 
revascularization 
Addition of plaque to risk score increase 
AUC from .742 to .751 
2011 Plichart et al. Three-City  5,895 Med. 5.4 yrs 
CVD death, MI, 
revascularization 
 
Plaque present HR=1.5 (1.0-2.2) 
 >2 plaques present HR=2.2 (1.6-3.1) 
2011 Polak et al 
Framingham 
Offspring 2,965 Avg. 7.2 yrs 
 
 
Composite Vascular 
Outcome (CVD death, 
MI, stroke, heart failure) HR=1.92 (1.49-2.47) 
2011 Xie et al.  
 
3,258 5 years MI 
 
 
≥3 plaquesHR=3.46 (1.89-6.35) 
2013 Polak et al. MESA 6,562 
 
Avg. 7.8 yrs CHD 
 
 
HR=1.67 (1.33-2.10) 
2015 Baber et al. 
 
BiolImage 5,808 3 yrs MACE 
 
 
HR=2.36 (CI=1.13-4.92) 
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Table 2.3 Femoral Plaque Presence as a Predictor of CVD Outcomes 
Year Author Study Name N Follow-Up Outcome Measure of Association 
2001 Held et al. APSIS 558 Med. 3 yrs 
CVD death, MI, 
revascularization 
 
CVD death/MI  RR=.86 (.43-1.71) 
Revascularization RR=1.93 (1.10-3.39) 
2008 Dalager et al. 
 
100 
 
 
Cross-sectional autopsy Coronary death 
 
 
OR=7.07 (2.40-20.81) 
2011 
McDermott  
et al. WALCS III 427 Cross-sectional   
Functional 
performance 
 
 
Slower paced usual walk p-trend<.0001  
Fastest-paced walk p-trend=.023 
2014 Frerix et al. 
 
190 4-6 yrs 
 
 
Composite  
CVD event 
 
 
HR=5.92 (1.55-22.67) 
2014 
Barone- 
Rochette et al. 
 
410 Cross-sectional 
 
 
Traditional  
risk factors 
 
 
OR=10.13 (5.94-17.30) 
2016 
Avramovski  
et al. 
 
101 4 yrs 
 
 
Composite  
CVD event 
 
 
HR=2.93 (1.43-6.01) 
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Table 2.4 B-Mode Ultrasound Characteristics of Plaque Verified by Histology 
 
 
 
Year Author N 
US Measured 
Characteristics 
Histologically  
Verified Characteristics Measure of Association 
1997 El-Barghouty et al. 52 Echogenicity 
Fibrous tissue, intraplaque 
hemorrhage, lipid content, 
calcification 
Echo-rich plaques associated with 
fibrous tissue (p=.03) and calcification 
(p=.01). Echolucent plaques associated 
with lipid content (p=.01). 
1997 Gronholdt et al. 246 GSM 
Lipid content,  
fibrous content 
 
Correlation between lipid content and 
GSM: r=-.351 (p<.05)  
Correlation between fibrous content 
and GSM: r=.411 (p<0.001) 
2005 Grogan et al. 48 GSM Necrotic core area 
Correlation between GSM and 
necrotic core: r=-0.9 (P<0.001) 
2014 Salem et al 126 Plaque area, GSM 
Composite Instability: 
hemorrhage, thrombus, 
inflammation, neovascularity,  
foam cells, cap rupture 
 
 
 
Plaque Area> 95 OR=4.15 (1.34-12.8)  
GSM<25 OR=3.76 (1.14-12.39) 
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Table 2.5 B-Mode Ultrasound Measured Characteristics of Plaque as Predictors of CVD Outcomes in Epidemiologic Studies 
Year Author N Artery 
US Measured 
Characteristic Outcome Follow-Up Measure of Association 
2001 Gronholdt et al. 346 Carotid Echogenicity  Stroke Avg. 4.4 yrs 
 
Echolucent Plaque RR=3.1 (1.3-7.4) 
2001 Hunt et al.  13,123 Carotid 
Calcification/ 
Acoustic 
Shadowing Stroke 8 yrs 
 
 
Women HR=4.01 (2.28-7.06)  
Men HR=2.23 (1.32-3.79) 
2004 Honda et al. 286 Carotid Echogenicity 
Coronary 
event risk 30 months 
 
 
Echolucent plaque OR=7.0 (2.3-21.4) 
2008 Reiter et al. 574 Carotid GSM MACE Avg. 3.2 yrs 
 
 
Lowest vs. highest GSM quartile  
HR=1.71 (1.09-2.66) 
2012 Schiano et al. 246 Femoral 
Echogenicity, 
GSM MI, stroke 30 months 
 
 
Echolucent plaque HR=7.24 (3.23-16.22)  
GSM HR=.96 (.95-.98) 
2015 de Kreutzenberg et al. 581 Carotid Calcification MACE Avg. 4.3 yrs 
 
 
Echogenic plaque HR=3.71 (2.09-5.59) 
2015 Thompson et al. 374 Carotid Calcification 
Mortality  
CVD event 11 yrs 
 
 
Mortality RR= 2.72 (1.4-2.51)  
CVD Event RR= 2.35 (1.5-3.8) 
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Table 2.6 Epidemiologic Studies of Perceived Everyday Discrimination and Subclinical CVD 
Year Author Study N Outcome Follow-Up Measure of Association 
2003 Troxel et al. SWAN (Pittsburgh) 334 
cIMT,  
Plaque Cross-sectional 
EDS score marginally associated with cIMT 
in full sample (p=0.06), and marginally 
associated with plaque index >1 in African 
American women (n=109) 
2006 Brown et al. SWAN 3,300 Blood Pressure Cross-sectional 
Marginal negative correlation between 
perceived discrimination with SBP and DBP 
in the total sample. No significant 
correlations among race/ethnicity subgroups 
2006 Cozier et al. 
Black Women's Health 
Study 30,330 
Incident 
Hypertension 4 Years 
IRR marginally significant for personally 
mediated racism (IRR=1.1 CI=1.0-1.3), no 
major differences based on neighborhood 
(predominately white, black, immigrant) 
2006 Lewis et al. 
SWAN (African 
American Participants 
from Pittsburgh & 
Chicago) 181 CAC 5 Years 
 
Chronic discrimination assessed by EDS 
marginally associated with CAC after 
adjustment for covariates (OR=2.6 CI=1.0-
6.47). Attribution of discrimination does not 
matter. 
2012 Sims et al. Jackson Heart Study 4,939 Hypertension Cross-sectional 
 
No associations seen with EDS; however 
discrimination burden (composite of multiple 
measures) was associated with greater 
likelihood of hypertension (OR= 1.09 
CI=1.02-1.16). Relationship was marginally 
significant after covariate adjustment. 
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2012 Klimentidis et al. 
Children recruited to 
UAB for metabolic 
cohort study 294 Blood Pressure Cross-sectional 
 
Perceived racial discrimination associated 
with SPB among African American 
participants (p=0.041) after adjusting for 
demographics, physical activity, and body fat. 
2012 Everage et al. CARDIA 1,362 CAC Cross-sectional 
 
EDS associated with lower odds of CAC 
(OR=0.93 CI=0.87-0.99) after adjustment for 
covariates. 
2013 Gregoski et al. 
Normotensive young 
adults in the Southern 
US 587 Ambulatory BP Cross-sectional 
 
Significant interaction between EDS and 
race/ethnicity in the prediction of daytime 
SBP (B=0.43 p=0.02) 
2015 Goosby et al. OURHealth Study 58 Blood Pressure Cross-sectional 
 
EDS positively associated with SBP (B=0.34 
p=<0.05), DPB (B=0.47 p=0.05), and CRP 
(B=0.34 p<0.05) after adjustment for 
demographics and BMI 
2016 Peterson et al. SWAN 1,056 
cIMT, 
Adventitial 
Diameter 
SWAN Visit 0 - 
Visit 10 
In Caucasian women, cumulative unfair 
treatments measured by EDS associated with 
cIMT (B=0.03 p=0.009) and adventitial 
diameter (B=0.02, p=0.013) after adjustment 
for covariates. No relationship seen among 
other racial/ethnic groups. 
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3.1 ABSTRACT 
Background: Atherosclerosis is a chronic inflammatory disease that results in the accumulation 
of plaque within the vessel wall of medium- and large-sized arteries. Biomarkers of 
inflammation including C-reactive protein (CRP), interleukin (IL)-6, and intracellular adhesion 
molecule (ICAM)-1, have been previously associated with atherosclerotic disease in the lower 
extremity vessels. We utilized an exploratory factor analysis (EFA) to identify distinct factors 
derived from circulating inflammatory and coagulation biomarkers, then examined the 
associations of these factors with measures of plaque presence, burden, and characteristics in the 
femoral artery.  
Methods: The San Diego Population Study (SDPS) is a prospective, population-based, multi-
ethnic cohort of 1103 men and women averaged age 70 at a follow-up exam taking place from 
2007-11. An EFA was conducted in order to identify the underlying structure of circulating 
inflammatory and coagulation markers collected during the SDPS follow-up exam including 
CRP, ICAM-1, IL-6, fibrinogen, D-dimer, Lipoprotein-a (LP(a)), and pentraxin-3 (PTX3). 
Regression analysis was utilized to measure associations between the identified grouping of 
biomarkers (factors) and plaque measures (presence, total number, total area, average grey-scale 
median, and presence of calcification) obtained via B-mode ultrasound of the right and left 
superficial and common femoral arteries. 
Results: Two biomarker factors emerged from the EFA: Factor 1 composed of CRP, IL-6, and 
fibrinogen, and Factor 2 composed of D-dimer and PTX-3. In unadjusted models, Factor 2 was 
associated with increased odds of plaque presence (OR=2.19 CI=1.47-3.25) and a greater 
number of plaques (OR=2.36 CI=1.64-3.32) in the femoral artery; however, these associations 
did not remain statistically significant after adjustment for CVD risk factors. No statistically 
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significant associations were identified between Factor 1 and characteristics of femoral plaque in 
this population.  
Conclusions: In this multi-ethnic, population-based cohort of predominately healthy aging men 
and women, two distinct groupings of biomarkers of seven circulating markers of inflammation 
and coagulation were identified via EFA. These factors were differentially associated with 
femoral plaque presence and burden, but neither factor was associated with femoral plaque 
characteristics. Additional studies utilizing this technique to assess populations with more 
progressive CVD may help elucidate the relationships between various biomarkers of 
inflammation and coagulation with specific atherosclerotic processes contributing to CVD. 
3.2 INTRODUCTION 
Atherosclerosis is a chronic inflammatory disease that occurs throughout the lifetime, and is the 
underlying disease process responsible for the majority of cardiovascular disease (CVD) 
morbidity and mortality (13, 23, 26, 200). Peripheral artery disease (PAD), one manifestation of 
atherosclerosis, affects an estimated 8.5 million individuals in the U.S. (201). PAD is associated 
with reduced functionality, increased risk of cardiovascular events, as well as cardiovascular and 
all-cause mortality (202-204).  
Subclinical measures of atherosclerosis have helped shape our understanding of the 
pathologic processes leading to CVDs including PAD (91, 103). These measures allow for the 
assessment of subclinical atherosclerosis in different stages of progression and for the 
identification of individuals at risk of cardiovascular events or complications. The detection of 
arterial plaque by B-mode ultrasound is an relatively inexpensive and non-invasive method of 
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directly identifying atherosclerosis, specifically, lesions present in the superficial arteries such as 
the carotid and femoral arteries (101). Plaque identified in the femoral artery is associated with 
reduced functional performance, plaque in the carotid and coronary arteries, and an increased 
risk of cardiovascular events and coronary death (90, 116, 205).  
In addition to the detection of plaque, plaque burden and characteristics may also be 
assessed via B-mode ultrasound. Increased femoral plaque burden, defined as total plaque area, 
is predictive of symptomatic peripheral artery disease (PAD) and lower functional performance 
(116, 206). Grey-scale median (GSM), a continuous measure of plaque echogenicity, can be 
utilized as a surrogate marker of plaque composition. In histologic studies, low GSM has been 
associated with lipid content, necrotic core presence, and composite measures of plaque 
instability (134-136). Conversely, higher GSM is correlated with greater fibrous content (134). 
In a prospective study of individuals with PAD, higher GSM of femoral artery plaque was found 
to be protective against the risk of myocardial infarction (MI) and ischemic stroke (149). 
Additionally, calcification, which can provide insight into the complexity and potential stability 
of plaque, may be measured via B-mode ultrasound (147, 207).  
Research investigating the inflammatory mechanisms contributing to atherosclerosis has 
led to the identification of circulating biomarkers of inflammation and coagulation, including  C-
reactive protein (CRP), intracellular adhesion molecule (ICAM)-1, interleukin (IL)-6, fibrinogen, 
D-dimer, Lipoprotein-a (LP(a)), and pentraxin-3 (PTX3), as independent predictors of 
cardiovascular risk (39, 43, 58, 64, 67, 208-214). Moreover, circulating levels of CRP, IL-6, and 
ICAM-1 have specifically been associated with PAD in longitudinal studies (41, 215, 216). 
However, less is known about the potential associations or involvement of these biomarkers in 
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the various stages of the development and progression of atherosclerotic disease, particularly in 
the lower extremity arteries.  
In the present study, we used an exploratory factor analysis (EFA) in order to determine 
if there is an underlying structure of seven circulating markers of inflammation and coagulation 
(CRP, IL-6, ICAM-1, fibrinogen, D-Dimer, PTX-3, and Lp(a)) in a population-based sample of 
health older adults. Next, we measured the associations of the biomarker groupings (factors) with 
various measures of plaque presence, burden, and characteristics in the common and superficial 
femoral arteries of healthy older adults.  
3.3 MATERIALS AND METHODS 
3.3.1 Participants 
The San Diego Study Population (SDPS) is a prospective, population-based, multi-ethnic 
cohort study of lower extremity PAD and venous disease in men and women averaged age 60 at 
baseline that has been described in detail elsewhere (217-219). Briefly, current and former 
employees of the University of California, San Diego and the significant others of these 
employees, all of whom resided in San Diego County, were recruited to participate in the study. 
Participants were selected randomly within strata of age, sex, and race/ethnicity. Women and 
racial/ethnic minorities (African-American, Hispanic, Asian) were over-sampled. The present 
study includes 1068 SDPS participants who had a femoral artery ultrasound completed during a 
follow-up exam between 2007-2011, on average 11 years after the baseline clinical examinations 
that took place between 1994-1998 (220). At the follow-up exam, participants ranged in age 
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from 48-94 years with a mean age of 70 years. The cohort was approximately 65% women, and 
60% non-Hispanic White, 15% Hispanic, 13% African American, and 12% Asian. All 
participants provided signed informed consent at both the baseline and follow-up examinations, 
and the University of California-San Diego Institutional Review Board Committee on 
Investigations Involving Human Subjects approved the study. 
3.3.2 Ultrasound Measurements 
Doppler ultrasound scans were conducted using an Acuson Aspen (Seimens, Inc) in order 
to obtain clips of three 10 mm segments of the right and left common and superficial femoral 
arteries: one at the common femoral artery (CFA) as it emerged from under the inguinal ligament 
proximal to the bifurcation, one at the bifurcation of the CFA and the superficial femoral artery 
(SFA) and one at the SFA distal to the bifurcation. Five-second image clips were obtained for 
these segments at an angle of isonation of 90 degrees. Regular quality control monitoring was 
performed throughout the study using images from 10-20 participants.  
Plaque presence and total number of plaques in each segment were determined by trained 
ultrasound readers at the University of Pittsburgh Ultrasound Research Laboratory (URL). 
Presence of plaque was defined using the Mannheim consensus criteria as a focal structure that 
encroaches into the arterial lumen at least 0.50 mm or 50% greater thickness than the 
surrounding IMT or that demonstrates a thickness > 1.5 mm as measured from the media-
adventitia border to the intima-lumen border (117). In some femoral segments, visualization of 
plaque presence was limited due to the presence of artifact. Focal structures fitting the 
Mannheim consensus identified in these images were classified as “probable plaques” by the 
readers. Plaque presence was defined as a participant having plaque in at least one arterial 
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segment (left SFA, right SFA, left CFA, or right CFA) and total number of plaques was defined 
as the sum of all plaques across the four arterial segments. 
Plaque area, GSM, and presence of calcification were determined by one trained 
ultrasound reader using semi-automated Carotid Analyzer software from the Vascular Research 
Tools 5 Suite (Medical Imaging Applications LLC, Coralville, IA). Plaque area for each plaque 
was calculated by the software once the plaque had been traced by the reader and automatically 
outlined by the software. Total plaque area was defined as the sum of plaque area in each of the 
four arterial segments. GSM, a continuous measure of plaque echogenicity, was calculated by the 
software for each plaque following grey level normalization. Normalization, which aims to 
minimize the effect of different ultrasound machine gain settings during image acquisition, was 
performed manually by the reader selecting a dark area of blood from the lumen and the brightest 
area of the adventitial layer along the anterior or posterior wall. Mean GSM was calculated by 
averaging the GSM values for all plaques in the four arterial segments. In a 2016 reliability study 
conducted by the URL, the within-reader intraclass correlation coefficients (ICC) for plaque area 
and GSM were .95 and .99, respectively. Calcification was subjectively identified by the reader 
after assessing each plaque for highly echogenic areas with or without acoustic shadowing. 
Presence of calcification was defined as a participant having a calcified plaque in at least one of 
the four arterial segments.  
3.3.3 Inflammatory and Coagulation Biomarkers 
Nephelometric assays on a BMI System (Siemens Heallthcare, Erlange, Germany) were 
used to measure C-reactive protein (CRP) and fibrinogen from EDTA plasma, and lipoprotein-
a(Lp(a)) in serum. Inter-assay coefficients of variation (CVs) were 4.1-5.1%, 3.2-4.7%, and 5.2-
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8.2% for CRP, fibrinogen, and Lp(a), respectively. Intercellular adhesion molecule (ICAM)-1 
was measured in EDTA plasma using a non-allele specific enzyme-linked immunosorbent assay 
(ELISA) (R&D Systems, Minneapolis, MN) with a CV range of 10.3-11.0%. ELISA was also 
used to measure pentraxin-3 (PTX3) in EDTA plasma and Interleukin(IL)-6 in serum with CVs 
of 9.3-14.9% and 4.2-6.3%, respectively. Finally, D-dimer was measured in EDTA plasma using 
an Evolution Coagulation Analyzer (Diagnostica Stago, Parsippany, NJ) with a CV range of 2.7-
24.7%. 
3.3.4 Covariates 
Age, sex, race/ethnicity, and current and former cigarette smoking habits were 
determined via self-report. Smoking habits were categorized as current, former, or never use of 
cigarettes. Height (centimeters) and weight (kilograms) was obtained in order to calculate body 
mass index (BMI) as kg/m2. CVD (previous MI, stroke, angioplasty, or revascularization) was 
also determined via self-report. Diabetes was ascertained via self-report, or the use of anti-
diabetic medications or insulin. Participants’ seated blood pressure was obtained from the right 
arm using a standard manual sphygmomanometer after five minutes of rest. Hypertension was 
defined as SBP ≥140 mmHg, diastolic blood pressure (DBP) ≥90, or the use of anti-hypertensive 
medications. Total and high density lipoprotein (HDL) cholesterol were measured from non-
fasting blood samples using a Roche Cobas 6000 analyzer (Roche Diagnostics Corporation, 
Indianapolis, IN). Low density lipoprotein (LDL) was calculated using the Friedewald equation 
(221). The CKD-Epi equation was used to calculate estimated glomerular filtration rate (eGFR), 
and a Roche Cobas 6000 analyzer (Roche Diagnostics Corporation, Indianapolis, IN) was 
utilized to measure serum creatinine levels via isotope dilution mass spectrometry (222). 
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Physical activity level was assessed via self-report by asking participants to rate their perceived 
activity level compared to other persons of their age. 
3.3.5 Statistical Analysis 
An exploratory factor analysis was performed in order to estimate the underlying 
structure of the seven measured inflammatory and coagulation biomarkers. Log transformed 
biomarker concentrations were calculated then extracted using maximum likelihood methods 
with direct oblimin rotation on Pearson correlation matrix using PROC Factor in SAS 9.3 (SAS 
Institute, Cary, NC). A scree plot and parallel analysis suggested that two factors should be 
retained. We compared the model fit and interpretability of models with one- through four-factor 
solutions, and retained the two-factor solution. Both the standardized root mean-square residual 
(SRMR) and the root mean square error approximation (RMSEA) indicate good fit of the two-
factor solution: SRMR = .028 and RMSEA = .032. Estimated factor scores were obtained via the 
SCORE option in PROC Factor based on the five biomarkers with loadings ≥|0.3| in the two-
factor solution. ICAM-1 and LP(a) were excluded from the final analysis since they did not load 
highly on any factor. Factor scores were categorized based on tertiles of the distribution.  
Chi-square and Kruskal-Wallis tests were used to compare differences in categorical and 
continuous participant characteristics, respectively, among those with and without femoral 
plaque and across tertiles of the factor scores. Chi-square and Kruiskal-Wallis tests were also 
used to measure the univariate associations between tertiles of factor scores and subclinical 
outcomes (plaque presence, total number of plaques, total plaque area, average GSM, and 
calcification). Logistic regression was used to assess the associations between the tertiles of 
factor scores with plaque presence and the presence of calcification. Linear regression was used 
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to determine associations between the tertiles of factor scores total plaque area and average 
GSM, and zero-inflated Poisson regression was used to determine associations between the 
tertiles of factor scores and total number of plaques. Minimally adjusted models included age, 
sex, and race/ethnicity, while fully adjusted models also included BMI, SBP, total cholesterol, 
eGFR, diabetes, smoking status, statin use, and self-reported activity level. All plaque variables 
include both the definite and “probable” plaques identified by ultrasound image readers. 
Sensitivity analyses were conducted excluding the 75 “probable” plaques (22%), but the 
exclusion of these plaques did not change the results. Similarly, sensitivity analyses were 
performed excluding those with diagnosed CVD (9%), CKD (14%), diabetes (10%), and PAD 
(3%). 
3.4 RESULTS 
Table 3.1 describes participant characteristics among those with and without plaque identified in 
at least one femoral segment. Participants with femoral plaque identified were older, more likely 
to be male, had higher SBP, and lower BMI compared to those without plaque. Those with 
plaque were also more likely to have hypertension, chronic kidney disease, PAD, and CVD, and 
on average had lower ABI compared to those without plaque. Additionally, circulating levels of 
IL-6, ICAM-1, D-dimer, and PTX-3 were significantly higher in those with plaque compared to 
those without plaque. A total of 1001 participants were included in the EFA based on the 
complete availability of biomarker data. The 67 participants who were excluded did not differ 
from those included in the final analysis (data not shown). Two factors were derived from the 
EFA Table 3.2. Factor 1 was composed of CRP, IL-6, and fibrinogen with factor loadings 
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ranging from .49-.83. Factor 2 was composed of D-dimer and PTX-3 with factor loadings 
ranging from .43-.48. ICAM-1 and LP(a) did not load on either factor. 
Age, systolic blood pressure, BMI, pulse pressure, and levels of all of the circulating 
biomarkers increased across tertiles of both Factor 1 and Factor 2 (Supplemental Table TO BE 
ADDED IN APPENDIX). Additionally, participants were more likely to be female, 
hypertensive, suffer from chronic kidney disease, and be less physically active across the 
increasing tertiles of both factors. HDL cholesterol decreased across the tertiles of Factor 1 only, 
and participants were more likely to use statins, or have PAD, CVD, or diabetes as the tertiles of 
Factor 2 increased.  
Approximately 25% (246) of the participants in the final analysis had at least one plaque 
present among the examined femoral artery segments. The maximum total number of plaques 
observed for a given participant was four, and among those with plaque, 66 participants (27%) 
had at least one calcified plaque.  In the univariate analyses, plaque presence, burden, and 
characteristics did not differ significantly across the tertiles of Factor 1 (Table 3.3). However, the 
prevalence of plaque presence, and the prevalence of >2 plaques present differed significantly 
across the tertiles of Factor 2 such that individuals in the higher tertiles of Factor 2 were more 
likely to have plaque present and a greater number of plaques. There were no significant 
differences in total plaque area, average GSM, or presence of calcification among the tertiles of 
Factor 2 in the univariate analysis.  
Table 3.4 displays the results of the multiple regression analysis measuring the 
associations between the biomarker factor scores and measures of plaque presence and plaque 
burden. There were no statistically significant associations between Factor 1 and plaque presence 
or plaque burden in unadjusted models (Model 1) or in models adjusted for confounding 
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variables (Models 2-3). In unadjusted models, the highest tertile of Factor 2 was associated with 
significantly increased odds of femoral plaque presence (OR=2.19 95% CI=1.48-3.25) compared 
to the lowest tertile. Factor 2 was also associated with an increased total number of plaques such 
that participants in the highest tertile of Factor 2 had a mean number of femoral plaques that was 
2.36 (95% CI=1.66-3.36) times higher than those in the lowest tertile. However, neither of these 
associations remained statistically significant following adjustment for covariates. There were no 
statistically significant associations between either Factor 1 or Factor 2 with the measures of 
plaque characteristics before or after adjustment for confounders (Table 3.5). The results of the 
various sensitivity analysis excluding participants diagnosed with probable plaques or CVD, 
CKD, diabetes, and PAD did not differ from the results described above. 
3.5 DISCUSSION 
In this multi-ethnic, population-based cohort of predominately healthy aging men and women, 
we utilized an EFA in order to identify two latent constructs underlying seven circulating 
biomarkers of inflammation and coagulation. Factor 1, composed of CRP, IL-6, and fibrinogen, 
was not associated with measures of femoral plaque presence, burden, or characteristics in our 
sample. In unadjusted models, Factor 2, composed of PTX-3 and D-dimer, was associated with 
increased likelihood of femoral plaque presence (OR=2.19 CI=1.47-3.25) and a greater number 
of plaques (OR=2.36 CI=1.64-3.32); however, these associations did not remain statistically 
significant after adjustment for demographics and comorbidities. Similar to Factor 1, Factor 2 
was not significantly associated with femoral plaque characteristics in the SDPS.  
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 We chose to utilize an EFA approach because due to the complex nature of 
atherosclerosis, many biomarkers of inflammation and coagulation are interdependent. These 
markers may in fact jointly contribute to the initiation or progression of pathologic processes 
involved in atherosclerosis. EFA is a technique that allows for the identification of underlying 
constructs, or factors, among a group of items with no a priori hypothesis (223, 224). The 
identification of groupings of circulating inflammatory and coagulation markers, or latent 
processes to which these markers contribute may not only provide insight into the relationships 
among these biomarkers, but may also help us to characterize patients who are at greatest risk 
(225). This approach differs from a principal components analysis, in that it is not a data 
reduction technique; therefore, EFA can help address concerns regarding multicollinearity 
without sacrificing information. Factor analyses, originally developed for social science research, 
have become increasingly common in epidemiologic research involving inflammation, nutrition, 
and metabolism due to their ability to simultaneously evaluate associations between many 
biomarkers with health outcomes (226-229). These types of techniques can shed light on the 
underlying biological relationships among biomarkers, and therefore, may prove particularly 
useful for the study of complex, multifaceted processes like atherosclerosis.  
 Our study identified two factors whose components were somewhat unanticipated but are 
plausible biologically. Factor 1, which seems likely to represent a non-specific inflammatory 
process, is composed of CRP, IL-6, and fibrinogen. The grouping of CRP and IL-6 was expected 
considering that CRP is synthesized by hepatocytes in response to IL-6 secretion by 
macrophages and T cells, and both are non-specific markers of inflammation with prognostic 
value in regards to CVD (39, 43, 208, 209). Fibrinogen is a glycoprotein that contributes to 
platelet aggregation and is converted to fibrin in order to form blood clots (214, 230). Similar to 
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CRP, fibrinogen is an acute phase reactant synthesized by hepatocytes in response to 
inflammation, and has been associated with risk of CHD and stroke (210, 230). The composition 
of Factor 2 (D-dimer and PTX3) is seemingly less straight-forward. PTX3 is an inflammatory 
protein and an activator of the classical complement pathway that is associated with numerous 
CVD outcomes including incident coronary heart disease (CHD), coronary artery calcium 
(CAC), PAD, and components of coronary plaques (67, 211-213). While both CRP and PTX3 
are members of the pentraxin superfamily, the results of our EFA suggest that PTX3 is more 
strongly correlated with D-dimer in this predominately healthy sample of older adults (64). 
Unlike CRP, PTX3 is a long pentraxin whose relationship with CVD is beyond the scope of 
inflammatory processes (63).  High levels of PTX3 have been observed within coronary arterial 
thrombi, and PTX3 increases the expression of Tissue Factor (TF), an activator of the 
coagulation cascade, in endothelial cells and lymphocytes (63, 64). D-dimer, a fibrin degradation 
product, is a marker of thrombogenesis that is present in the blood following the activation of the 
coagulation cascade (231, 232). Like PTX3, D-dimer is associated with increased risk of CHD in 
prospective studies (58, 233). Thus, the grouping of these two biomarkers within Factor 2 may 
be indicative of a thrombogenic process.  
The association of Factor 2 with plaque presence and burden in unadjusted models 
suggests that coagulation burden may be more important in regards to femoral plaque 
development than inflammatory burden in this older population. Although we did not find any 
statistically significant associations between our factors and plaque measures, each biomarker 
included in our analysis has been previously associated with plaque (45, 213, 234-236). The 
majority of these prior studies examine samples consisting of participants who are already 
clinically diagnosed with CVD. Studies examining femoral plaque presence and burden report 
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strong associations between plaque presence with low ABI and symptomatic PAD (116, 206, 
237). Our cross-sectional study included active, healthy, adults averaged age 70 among whom 
only 25% had femoral plaque, 9% had CVD, and 3% had PAD. The limited burden of femoral 
artery atherosclerosis in our study sample may have contributed to our null findings due to the 
fact that there may not have been sufficient plaque or heterogeneity of plaque characteristics in 
order to see associations with our factors. The specific inflammatory and coagulation markers 
measured in this study may be better indicators of later atherosclerotic disease processes than 
what was present in our sample. Additionally, the relationships between these biomarker factors 
and measures of plaque characteristics may be different if examined in another arterial bed, like 
the carotid artery, where atherosclerotic plaque is more likely to be high-risk (238).  
 Strengths of our study include the large, multi-ethnic, population-based sample of 
participants who underwent standardized clinical examinations and ultrasound examination 
conducted by trained technicians. Our statistical methodology allowed us to simultaneously 
model the effects of several biomarkers of inflammation and coagulation, and we performed 
sensitivity analysis excluding femoral plaques that were difficult to visualize via ultrasound. 
While the use of B-mode ultrasound is a non-invasive and efficient method of measuring plaque 
in the general population, B-mode ultrasound is limited in its ability to characterize plaque. GSM 
is a surrogate marker of plaque components, and calcification is subjectively assessed by an 
ultrasound reader. These measures may not have been sufficiently sensitive to identify 
associations between the biomarker factors and plaque characteristics in this population with 
relatively little femoral plaque. Additionally, the cross-sectional nature of this investigation 
limits our ability to draw conclusions regarding the causal relationships, or lack thereof, between 
the biomarker factors and plaque measures. Finally, only seven biomarkers were included in our 
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analysis, two of which did not load on either of the identified factors. The consideration of 
additional biomarkers in the EFA may have yielded additional factors incorporating ICAM-1 and 
Lp(a), although these markers were not individually associated with any of the outcomes in this 
study. 
 In conclusion, two factors emerged following an EFA of seven circulating biomarkers of 
inflammation and coagulation; however, neither factor was associated with measures of femoral 
plaque presence, burden, or characteristics in the SDPS after adjustment for covariates. EFA is a 
useful method that can help shed light on the interdependencies of inflammatory and coagulation 
biomarkers in relation to the development of CVD. Further studies are needed in populations 
with more advanced CVD in order to elucidate the relationship between circulating biomarker 
groups with specific atherosclerotic processes contributing to CVD. 
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3.6 TABLES  
Table 3.1 Characteristics of San Diego Study Participants by Plaque Presence 
Characteristic Plaque (N=262) No Plaque (N=806) p-value
Age (years) 77 (70-83) 68 (61-76) <0.0001 
Sex (male) 101 (39%) 250 (31%) 0.0274 
Race/Ethnicity 0.0002 
Non-Hispanic White 189 (72%) 451 (56%) 
African-American 22 (8%) 108 (13%) 
Hispanic 22 (8%) 128 (16%) 
Asian 28 (11%) 106 (13%) 
 Systolic BP (mmHg) 132 (120-146) 130 (118-140) 0.0016 
Diastolic BP (mmHg) 72 (65-80) 76 (70-82) <0.0001 
Body Mass Index (kg/m2) 25.53 (23.10-28.37) 26.56 (23.59-30.11) 0.0065 
Estimated GFR 
(min/mL/1.73m2) 73.99 (58.40-85.95) 82.62 (69.28-92.85) <0.0001 
Total Cholesterol (mg/dL) 190 (164-213) 197 (170-226) 0.0029 
HDL Cholesterol (mg/dL) 58 (44-71) 57 (45-72) 0.5884 
LDL Cholesterol (mg/dL) 104 (80-125) 107 (87-132) 0.0079 
Pulse Pressure 61.4 (50.0-70.0) 54.2 (42.0-62.5) <0.0001 
Smoking History 0.0312 
Current 10 (4%) 29 (3%) 
Former 94 (36%) 222 (28%) 
Never 156 (60%) 550 (69%) 
 Hypertension 194 (74%) 471 (58%) <0.0001 
Statin Use 101 (40%) 241 (31%) 0.0059 
Cardiovascular Disease  40 (15%) 53 (7%) <0.0001 
Diabetes 38 (15%) 68 (8%) 0.0043 
Chronic Kidney Disease  70 (28%) 90 (11%) <0.0001 
Peripheral Artery Disease 24 (9%) 12 (1%) <0.0001 
Ankle Brachial Index  1.12 (1.04-1.18) 1.14 (1.09-1.19) 0.0003 
Activity Level  3.7 (3.5-3.8) 3.6 (3.4-3.7)  0.6735 
CRP (mg/L) 1.17 (.58-2.34) 1.02 (.5-2.17) 0.1582 
IL-6 (pg/mL) 2.07 (1.41-3.14) 1.72 (1.13-2.64) <0.0001 
ICAM-1 (ng/mL) 357.20 (297.96-432.33) 340.49 (285.16-412.04) 0.0459 
Fibrinogen (mg/mL) 386 (335-433) 380.00 (333.00-429.00) 0.7365 
D-dimer (ug/mL) 0.46 (.26-.77) 0.40 (.21-.65) 0.0014 
LP(a) (g/L) 0.15 (.04-.34) 0.11 (.04-.35) 0.3068 
PTX-3 (ng/mL) 1.34 (.90-1.96) 1.23 (.81-1.79) 0.0224 
a Median (25th-75th) provided for all continuous variables, Kruskal-Wallis test used to compare 
groups.  
b N (%) provided for categorical variables, Chi-square test used to compare group 
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Table 3.2 Rotated Factor Loadings based on Exploratory Factor Analysis 
Factor 1: Factor 2: 
CRP 0.83 - 
IL-6 0.52 - 
Fibrinogen 0.49 - 
D-Dimer - 0.43
PTX-3 - 0.48
ICAM-1 - -
LP(a) - - 
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Table 3.3 Differences in Plaque Outcomes by Tertiles of Biomarker Factor Scores 
a Median (25th-75th) provided for all continuous variables, Kruskal-Wallis test used to compare groups. 
b N (%) provided for categorical variables, Chi-square test used to compare groups 
Factor 1: CRP, IL-6, Fibrinogen Factor 2: PTX-3, D-dimer 
T1 T2 T3 p-value T1 T2 T3 p-value
Plaque Presence 68 (21%) 84 (25%) 94 (28%) 0.0921 62 (19%) 68 (21%) 116 (34%) <.0001 
Total # of Plaques 0.2481 
 
0.0083 
<=2 65 (96%) 74 (88%) 84 (89%) 59 (95%) 63 (93%) 101 (87%) 
>2 3 (4%) 10 (12%) 10 (11%) 3 (5%) 5 (7%) 15 (13%) 
Total Area 11.7 (8.2-36.7) 13.4 (9.3-24.6) 12.3 (8.4-21.3) 0.5148 14.2 (8.3-21.7) 12.0 (8.3-21.2) 12.6 (8.7-25.9) 0.6356 
Average GSM 52.9 (39.8-59.8) 56.5 (42.7-73.3) 55.3 (44.2-68.1) 0.1956 49.6 (40.9-62.3) 56.5 (42.0-74.9) 55.5 (44.7-65.9) 0.1848 
Calcification 19 (28%) 21 (25%) 26 (28%) 0.8963 13 (21%) 17 (25%) 36 (31) 0.3253 
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Table 3.4 Associations of Biomarker Factor Scores with Femoral Plaque Presence and Burden 
  Outcome 
  Plaque Presence # of Plaques 
Biomarker Factor Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 
 
Factor 1: CRP, IL-6, Fibrinogen 
Tertile 1 (ref) - - - - - - 
Tertile 2  .13(.19) -.03(.20) -.01(.21) .21(.17) .17(.17) .15(.17) 
Tertile 3 .05(.21) .12(.22) .21(.23) .04(.18) .18(.17) .25(.18) 
 
Factor 2: PTX-3, D-dimer 
Tertile 1 (ref) - - - - - - 
Tertile 2  .10(.20) -.26(.22) -.25(.27) .23(.19) -.00(19) .01(.19) 
Tertile 3 .78(.20) ‡ .04(.24) .08(.24) .86(.18) ‡ .33(.20) .28(.20) 
 
a Beta estimates (se) provided. ‡ indicates significant at α=.05 level.  
b Model 2 adjusts for age, sex, and race/ethnicity.  
c Model 3 adjusts for Model 2 + BMI, SBP, total cholesterol, eGFR, diabetes, smoking status, statin use, and activity level. 
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Table 3.5 Associations of Biomarker Factor Scores with Plaque Presence 
  Outcome 
  Plaque Area Average GSM Calcification 
Biomarker 
Factor Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 
  Factor 1: CRP, IL-6, Fibrinogen 
Tertile 1 (ref) - - - - - - - - - 
Tertile 2 .01 (2.69) -.90 (2.60) -.81 (2.68) .34 (5.32) .72 (5.29) .90 (5.44) -.37 (.40) -.40 (.40) -.37 (.43) 
Tertile 3 -.94 (2.87) -1.43 (2.73) -.68 (2.87) -1.06 (5.45) -2.11 (5.45) -2.60 (5.77) -.33 (.41) -.27 (.41) -.14 (.44) 
  Factor 2: PTX-3, D-dimer 
Tertile 1 (ref) - - - - - - - - - 
Tertile 2 -.16 (2.89) 1.86 (2.92) 1.55 (2.93) 4.10 (5.78) 4.38 (5.95) 4.76 (6.02) .38 (.45) .29 (.49) .16 (.50) 
Tertile 3 3.55 (2.76) 5.53 (2.96) 4.58 (3.00) 2.05 (5.35) 4.34 (5.88) 4.76 (6.04) .70 (.42) .52 (.29) .26 (.51) 
 
a Beta estimates (se) provided. ‡ indicates significant at α=.05 level.  
b Model 2 adjusts for age, sex, and race/ethnicity.  
c Model 3 adjusts for Model 2 + BMI, SBP, total cholesterol, eGFR, diabetes, smoking status, statin use, and activity level 
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4.1 ABSTRACT 
Introduction: Inflammation is one of the primary mechanisms driving atherosclerosis, a process 
which has been postulated to accelerate among women in midlife. Questions remain regarding 
the role that circulating inflammatory and coagulation burden may play in progression of 
atherosclerosis in midlife women. Better understanding of the relationships between 
inflammatory and coagulation burden with measures of subclinical atherosclerotic plaque may 
help shed light on the mechanisms contributing to the dramatic increase in CVD risk observed in 
women at midlife. 
Methods: A sample of 277 late peri- and postmenopausal women free of clinical CVD 
underwent a blood draw and bilateral carotid ultrasound for the measurement of carotid plaque. 
We conducted an exploratory factor analyses (EFA) in order to identify distinct groupings of 
circulating inflammatory and coagulation biomarkers including CRP, IL-6, fibrinogen, D-dimer, 
Factor VII, and vwAntigen. Factor scores were calculated based on the results of the EFA, and 
multiple regression was used to measure the associations between the biomarker factors and 
measures of plaque presence, burden (total area, total number of plaques), and characteristics 
(maximum height, minimum grey scale median (GSM), and calcification). Interactions were 
tested between the factors derived from the EFA with race/ethnicity, hot flashes, sleep, years 
since final menstrual period (FMP), and BMI.  
Results: No significant associations were observed between either factor or the various 
subclinical measures among the complete MS Heart sample. Significant interactions were 
observed between continuously modeled BMI and the factors when predicting total number of 
plaques (p=0.02 and p<0.01 for =Factors 1 and 2, respectively) and total plaque area (p=0.03 for 
Factor 2). Among women with normal BMI (<25kg/m2, n=98), Factor 1 (composed of CRP, IL-
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6, and fibrinogen) and Factor 2 (composed of D-dimer and vwAntigen) were associated with a 
greater total number of plaques (OR=2.75 95% CI=1.56-4.85, and OR=1.81 95% CI=1.09-3.02 
for Factors 1 and 2, respectively). The association between Factor 2 and total number of plaques 
remained significant after adjustment for demographics, traditional CVD risk factors and 
medication use. Among women of normal BMI, Factor 1 was also associated with greater total 
plaque area (B=24.70, p=0.03) in minimally adjusted models, but not after adjustment for 
traditional CVD risk factors.  
Similarly, interactions were observed between continuously modeled time since final 
menstrual period (FMP) and the factors when predicting minimum GSM (p=0.07 and p=0.03 for 
Factors 1 and 2, respectively) and maximum plaque height (p=0.04 and p=0.01 for Factors 1 and 
2, respectively). Among women with <1 years since their FMP (n=56), Factor 1 was 
significantly associated with greater maximum plaque height after adjustment for demographics 
and medication use (B=2.05 p=0.01) and borderline associated after adjustment for traditional 
CVD risk factors (B=1.76 p=0.05). Among women with ≥ 1 year since their FMP (n=248), 
Factor 1 was associated with lower minimum GSM (-28.29 p=0.01) after adjustment for 
demographics and medication use, but not after adjustment for traditional risk factors. 
Discussion: Higher circulating inflammatory and coagulation burden is associated with greater 
plaque burden in the carotid artery of midlife women with normal BMI. Higher inflammatory 
burden is also associated with greater maximum plaque height among perimenopausal women.  
These findings highlight important associations between circulating inflammatory and 
coagulation burden with measures of carotid plaque in midlife women, and suggest that the 
inflammatory and coagulation processes represented by these EFA-derived factors may serve as 
mechanisms contributing to the progression of atherosclerotic plaque in midlife women.  
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4.2 INTRODUCTION 
Midlife is a period marked by dramatic changes in women’s cardiovascular health (239). 
Atherosclerotic CVD, the leading cause of death among women, manifests on average 10 years 
later in women compared to men (240, 241). Evidence suggests that during the menopausal 
transition, atherosclerosis is accelerated, and CVD risk increases to reach that of men (240, 242).  
Inflammation is one of the driving forces of CVD development and the progression of 
atherosclerosis (25, 26). The study of inflammatory mechanisms contributing to atherosclerosis 
has led to the identification of circulating biomarkers of inflammation and coagulation such as 
CRP, IL-6, fibrinogen, D-dimer, and Factor VII as independent predictors of cardiovascular risk 
(58, 208-210, 243). Furthermore, higher circulating CRP, IL-6, fibrinogen, and D-dimer levels 
have been associated with unstable and symptomatic atherosclerotic plaques in the carotid artery 
(56, 244). Still, relatively little is known about how these inflammatory and coagulation markers 
may jointly contribute to atherosclerotic plaque progression, erosion, and rupture, or how 
circulating inflammatory and coagulation burden may contribute to the increase in CVD risk 
observed among women in midlife. 
Measures of subclinical atherosclerosis, such as B-mode carotid ultrasound, allow for the 
assessment of atherosclerotic plaque in different stages of progression (103, 245). B-mode 
ultrasound is an inexpensive and noninvasive method that allows for the direct identification of 
plaque in the carotid artery (101).  Carotid plaque is associated longitudinally with increased risk 
of stroke (100, 246), MI (247) , MACE (128, 248), and cardiovascular death (127, 249, 250). In 
addition to identifying prevalent atherosclerotic plaque, B-mode ultrasound can be used to assess 
plaque burden and to characterize plaques found in the carotid artery.  Greater plaque burden, 
defined by plaque area, is associated with increased risk of stroke (124), MI (125, 126), and 
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MACE (120). Grey-scale median (GSM), a continuous measure of plaque echogenicity that may 
be obtained via B-mode ultrasound, is a surrogate marker of plaque components. Low GSM has 
been associated with increased lipid content, necrotic core presence, and composite measures of 
plaque instability in histologic studies (134-136). Conversely, higher GSM is correlated with 
greater fibrous content among plaques assessed via histology (134). Lower GSM plaque in the 
carotid artery is prospectively associated with increased hazard of MACE among asymptomatic 
individuals with carotid artery disease (148). Other characteristics of plaque that may be obtained 
via B-mode ultrasound, such as plaque height and calcification, which are both susceptible to 
changes following the initiation of statin therapy, may provide further insight into the complexity 
and potential stability of carotid plaques (251, 252). Greater plaque height is longitudinally 
associated with greater risk of cardiovascular events (253, 254). Additionally, individuals with 
calcified carotid plaque have a higher risk of mortality and cardiovascular events compared to 
those who do not have plaque (150, 151). However, studies documenting an increase in 
calcification of plaque following the initiation of statin treatment suggest that calcification may 
be a beneficial characteristic of plaque among those with high plaque burden (252, 255).   
The purpose of the present study is to identify distinct factors following an EFA of six 
circulating markers of inflammation and coagulation (CRP, IL-6, fibrinogen, D-Dimer, Factor 
VII, and vwAntigen) in a sample of midlife women, then determine whether the identified 
factors are associated with plaque presence, burden, and characteristics in the carotid arteries of 
women at midlife. We hypothesize that higher inflammatory and coagulation burden are 
associated with greater plaque burden, and that higher inflammatory burden is associated with B-
mode ultrasound-identified characteristics of plaque that are indicative of instability including 
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lower GSM, greater maximum height, and reduced calcification among those with prevalent 
carotid atherosclerosis. 
4.3 MATERIALS AND METHODS 
4.3.1 Participants 
The MS Heart Study comprises of 304 late perimenopausal (2-12 months amenorrhea) 
and postmenopausal (≥12 months amenorrhea) nonsmoking women aged 40-60 years. 
Participants were recruited through advertisements, mailings, fliers, referral from local clinics, 
and online message boards for a study investigating the relationship between vasomotor 
symptoms and CVD risk. By design, half of them women reported daily hot flashes or night 
sweats within the past three months, and half of the women reported no hot flashes or night 
sweats in the past three months. Women were excluded from the study if they had previously had 
a hysterectomy and/or bilateral oophorectomy, history of heart disease, stroke, arrhythmia, 
ovarian/gynecological cancer, pheochromocytoma, pancreatic tumor, kidney failure, seizures, 
Parkinson’s disease, Raynaud phenomenon, endarterectomy, endometrial ablation, were 
currently pregnant, or had used the following medications in the past three months: 
oral/transdermal estrogen or progesterone, selective estrogen receptor modulators, selective 
serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, gabapentin, insulin, 
beta blockers, calcium channel blockers, alpha-2 adrenergic agonists, or other antiarrhythmic 
agents. Additionally, women currently undergoing dialysis or chemotherapy were excluded.  
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Upon inclusion in the study, participants underwent physical measurements, 
questionnaire completion, blood draw, ambulatory physiologic hot flash monitoring for three 
days, electrocardiogram, actigraphic sleep monitoring, and a carotid artery ultrasound. 
Procedures were approved by the University of Pittsburgh Institutional Review Board, and all 
participants provided written informed consent.  
The present analysis includes 277 women from the MS Heart Study sample for whom all 
biomarker data was available. Four women were excluded from the analysis because their 
circulating il-6 levels were extreme outliers (>12pg/mL), and 23 women were excluded due to 
missing values for at least one of the biomarkers assessed in the exploratory factor analysis. The 
27 excluded women were significantly more likely to be non-white, and had higher BMI, insulin, 
and HOMA compared to those who were included in the analysis (data not shown). 
4.3.2 Ultrasound Measurements and Plaque Characterization 
Bilateral carotid images were obtained via B-mode ultrasound using a Sonoline Antares 
(Siemens, Malvern, PA) high-resolution duplex scanner with a VF10-5 transducer by trained 
sonographers at the University of Pittsburgh Ultrasound Research Laboratory (URL) according 
to a standardized protocol. Five carotid segments within both the left and right carotid arteries 
were assessed for plaque: the proximal common carotid artery (CCA), the distal common carotid 
artery (CCA one centimeter distal to the carotid bulb), the carotid bulb (where the near and far 
walls of the common carotid are no longer parallel, extending to the flow divider), the internal 
carotid artery (ICA), and the external carotid artery (ECA).  
Consistent with the Mannheim Consensus Statement, presence of plaque was defined as a 
focal structure that encroaches into the arterial lumen with 50% greater thickness than the 
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surrounding intima-media thickness (117). Plaque presence and total number of plaques in each 
segment were determined by trained ultrasound readers. Plaque presence was defined as a 
participant having plaque in at least one arterial segment and total number of plaques was 
defined as the sum of all plaques across all of the visualized arterial segments. One trained 
ultrasound reader determined plaque area, height, GSM, and presence of calcification by one 
ultrasound reader using semi-automated Carotid Analyzer software from the Vascular Research 
Tools 5 Suite (Medical Imaging Applications LLC, Coralville, IA). Plaque area for each plaque 
was calculated by the software once the plaque had been traced by the reader and automatically 
outlined by the software. Total plaque area was defined as the sum of plaque area in each of the 
arterial segments. GSM was calculated by the software for each plaque following grey level 
normalization, which aims to minimize the effect of different ultrasound machine gain settings 
during image acquisition. Normalization was performed manually by the ultrasound reader 
selecting the darkest area of blood from the lumen and the brightest portion of the adventitial 
layer along the anterior or posterior wall. Maximum height was defined as greatest plaque height 
value for each participant with plaque present. Minimum GSM was defined as the GSM value of 
the plaque with the lowest GSM for each participant with plaque present. The reader subjectively 
identified calcification after assessing each plaque for highly echogenic areas with or without 
acoustic shadowing. Presence of calcification was defined as a participant having a calcified 
plaque in at least one of the visualized arterial segments.  
4.3.3 Inflammatory and Coagulation Biomarkers 
A high-sensitivity reagent set (Beckman Coulter, Brea, CA, USA) was used to measure 
hsCRP, and IL-6 was measured using an R&D Systems high sensitivity enzyme-linked 
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immunosorbant assay (Minneapolis, MN, USA). Fibrinogen was measured using a modified 
Clauss method and Siemens Multifibren U reagent (Newark, DE, USA), and quantitative D-
dimer was measured using a Diagnostica Stago’s Asserachrom assay (Asnieres sur Seine, 
France). Factor VII clotting activity was measured using standard clotting methods via a Siemens 
Innovin thromboplastin reagent with Factor VII-deficient plasma (HRF, Raleigh, NC, USA), and 
vWF Antigen was assessed using Diagnostica Stago’s STA-Liatest reagent (Asnieres sure Seine, 
France).  
4.3.4 Covariates and Additional Measures 
Participants self-reported their race/ethnicity, education level, shift work, medical and 
psychiatric history, health behaviors, and medication use (BP lowering, lipid lowering, diabetes, 
depression, anxiety, sleep) via questionnaire.  Height and weight were measured using a fixed 
stadiometer and a balance beam scale in order to calculate BMI. Resting BP was measured using 
a Dinamap device after a seated 10-minute rest period, and the final BP was defined as the 
average of the second and third BP reading. Menopausal status was categorized as 
perimenopausal (>2-<12 months amenorrhea) or postmenopausal (≥12 months amenorrhea) 
(256). Participants also completed the Pittsburgh Sleep Quality Index (PSQI) in order assess 
sleep quality (257) and the Berlin Sleep Questionnaire in order to assess sleep apnea symptoms 
such as snoring (258). Glucose, total cholesterol, triglycerides, and HDL, were assessed 
enzymatically (Vital Diagnostics, Lincoln, RI) following a blood draw that took place after a 12-
hour fast, and LDL was calculated using the Friedewald equation (221). Insulin level was 
measured by radioimmunoassay, and HOMA was calculated. Sex hormone binding globulin 
(SHBG) was measured using chemiluminescent assay. 
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Measurement of physiologic hot flashes in the MS Heart sample has been described in 
detail elsewhere (259). Briefly, physiologic hot flashes were monitored over a 24-hour period 
using sternal skin conductance monitoring (260, 261). A VU-AMS monitor (VU University 
Amsterdam, Netherlands) was used to sample skin conductance from the sternum at 1 Hz from 
two Ag-Ag Cl electrodes. For the present analysis, participants were categorized into groups 
consisting of those who experienced physiologic hot flashes over the 24-hour monitoring period 
and those who did not. 
4.3.5 Statistical Analysis 
An exploratory factor analysis was performed in order to estimate the underlying 
structure of the six measured inflammatory and coagulation biomarkers. Biomarker 
concentrations were log transformed and then extracted using maximum likelihood methods with 
direct oblimin rotation on Pearson correlation matrix using PROC Factor in SAS 9.3 (SAS 
Institute, Cary, NC). A scree plot and parallel analysis suggested that two factors should be 
retained. We compared the model fit and interpretability of models with one- through three-
factor solutions, and retained the two-factor solution based on model fit statistics. Estimated 
factor scores were obtained via the SCORE option in PROC Factor based on the five biomarkers 
with loadings ≥|0.3| in the two-factor solution. Factor VII did not load on any factor and was 
therefore excluded from the remainder of the analysis. Factor scores were then categorized based 
on tertiles of the distribution.  
Chi-square and Kruskal-Wallis tests were used to compare differences in participant 
characteristics across tertiles of the factor scores. Similarly, in order to measure the univariate 
associations between tertiles of factor scores and plaque outcomes (plaque presence, total 
78 
number of plaques, total plaque area, maximum height, minimum GSM, and calcification) Chi-
square and Kruskal Wallis tests were used. Logistic regression was used to assess the 
associations between the tertiles of factor scores with plaque presence and the presence of 
calcification. Linear regression was used to determine associations between the tertiles of factor 
scores total plaque area, maximum height, and minimum GSM. Finally zero-inflated Poisson 
regression was used to determine associations between the tertiles of factor scores and total 
number of plaques. Models were initially unadjusted, then adjusted for age, race, and self-rated 
health (Model 2). Separate models were used to adjust for CVD risk factors including BMI, SBP, 
HDL-C, HOMA, PSQI, physiologic hot flashes and time since FMP (Model 3), as well as 
medication use including lipid lowering, blood pressure, anti-diabetics, and sleep medications 
(Model 4). Interactions were tested for using cross product terms in models. When significant 
interactions were identified among continuous variables, PROC PLM in SAS 9.3 (SAS Institute, 
Cary, NC) was used to compare effects at various levels of the continuous moderators. All 
analyses were performed using SAS 9.3 (SAS Institute, Cary, NC).  
4.4 RESULTS 
Table 4.1 details the characteristics of participants included in the EFA. Briefly, participants 
were on average 54 years old, overweight, predominately white, and approximately 46% of study 
participants had plaque present in at least one segment of the carotid artery. Two factors emerged 
from the EFA (Table 4.2). Factor 1 was composed of CRP, IL-6, and fibrinogen, with factor 
loadings ranging from 0.38-0.99. Factor 2 was composed of D-dimer and vWF antigen with 
factor loadings ranging from 0.39-0.63. Factor VII did not load on any factor. BMI, SBP, DBP, 
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insulin, HOMA, estrone, estradiol, and each of the circulating inflammatory and coagulation 
markers increased over the increasing tertiles of both Factor 1 and Factor 2 (Table 4.3). 
Additionally, across the increasing tertiles of Factor 1 and Factor 2 individuals were more likely 
to have lower self-rated health, lower HDL-C, utilize medication for hypertension, and be 
considered high risk based on the Berlin Sleep Questionnaire. Across the increasing tertiles of 
Factor 1, participants were significantly more likely to have difficulty paying for basics, have 
higher blood glucose levels, higher triglycerides, and lower SHBG, while across the increasing 
tertiles of Factor 2 participants were significantly more likely to be on medication for diabetes, 
have higher LDL-C, and more likely to report snoring. There were no differences in plaque 
presence, total number of plaques, minimum plaque GSM, maximum plaque height, and 
presence of calcification across the tertiles of Factor 1 and Factor 2 in univariate models (Table 
4.4).  
In the regression analyses, there were no statistically significant associations observed 
between either Factor 1 or Factor 2 with measures of plaque presence and burden in the total MS 
Heart sample (Table 4.5). However, significant interactions were observed between Factor 1 and 
BMI when predicting plaque presence (B=0.20, p=0.016) and total plaque area (B=0.14, p=0.01), 
and also between Factor 2 and BMI when predicting plaque presence (B=-0.24, p<0.01), total 
number of plaques (B=1.08, p=0.03), and total plaque area (B=-0.18, p<0.01). After stratification 
by BMI (<25 kg/m2 vs. ≥25 kg/m2), a significant association was observed between Factor 1 and 
a greater total number of plaques (OR=1.81 95% CI=1.09, 3.02) among women with BMI <25 
kg/m2 (n=98); however, this association did not remain significant after adjustment for 
covariates. Additionally, the highest tertile of Factor 1 was associated with greater plaque area in 
unadjusted models (B=24.70, p=0.03) and after adjustment for medication use (B=33.45, 
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p=0.04), but not after adjustment for CVD risk factors (Figure 4.2). Similarly, a significant 
association was observed between Factor 2 and total number of plaques such that among women 
with BMI<25 kg/m2, such that those in the highest tertile of Factor 2 had a mean number of 
plaques that was 2.75 (95% CI=1.56, 4.85) times higher than those in the lowest tertile (Figure 
4.1). This relationship remained significant after adjustment for CVD risk factors (OR=2.10 95% 
CI=1.15, 3.82) as well as after adjustment for medication use (OR=2.64 95% CI=1.45, 4.81). 
Among those with BMI ≥25 kg/m2 (n=206) there were no significant associations between either 
of the biomarker factors and the various measures of plaque presence or burden. Scatter plots 
depicting the relationship between Factor 1 and BMI among the BMI-stratified groups (<25 
kg/m2 and ≥25kg/m2) can be found in Appendix A.  
Similarly, there were no significant associations between either of the biomarker factors 
with the measures of plaque characteristics in the entire sample (Table 4.6). However, significant 
interactions were observed between both Factors 1 and 2 with time since final menstrual period 
(FMP) when predicting maximum height (B= -0.03 p=0.04 and B=0.04 p=0.01 for Factors 1 and 
2, respectively), and between Factor 2 with time since FMP when predicting minimum plaque 
GSM (B=-1.29 p=0.03). After stratifying the sample based on years since FMP (<1 year vs. ≥1 
year), a significant association was observed between Factor 1 and maximum plaque height 
among women with <1 years since their FMP (n=56) such that those in the highest tertile of 
Factor 1 had a maximum plaque height an average of 1.51 mm greater than those in the lowest 
tertile (p=0.04). This association remained significant (B=1.76 p=0.05) after adjustment for CVD 
risk factors (Figure 4.3). In unadjusted models the highest tertile of Factor 2 was associated with 
a maximum plaque height 1.13 mm lower than those in the lowest tertile; however this 
relationship was not significant after adjustment for CVD risk factors. There were no 
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associations between either factor and maximum plaque height among women with ≥1 year since 
their FMP. 
Among women with ≥1 year since their FMP (n=248), the highest tertile of Factor 1 was 
significantly associated with lower minimum GSM (B=-28.29 p=0.01), but this association was 
attenuated after adjustment for CVD risk factors (Figure 4.3). Conversely, among this same 
group, Factor 2 trended toward an association with higher minimum GSM. There were no 
significant associations between either factor and minimum GSM among women with <1 year 
since their FMP. There were no significant interactions between the factors and age, menopausal 
stage, race/ethnicity, sleep, or hot flashes when predicting the plaque outcomes.  
4.5 DISCUSSION 
In a sample of 277 midlife women, two factors emerged following an EFA of circulating 
biomarkers of inflammation and coagulation: Factor 1 composed of CRP, IL-6, and fibrinogen, 
and Factor 2 composed of D-dimer and vwAntigen. Significant interactions were observed 
between both factors and BMI when predicting plaque burden. Among women with BMI 
(<25kg/m2), both factors were associated with an increased total number of plaques in the carotid 
artery. The association between Factor 2 and total number of plaques was independent of 
traditional CVD risk factors and medication use. Factor 1 was also associated with greater total 
plaque area after adjustment for demographics and medication use, but not traditional CVD risk 
factors.  
Similarly, significant interactions were observed between both factors and time since 
FMP when predicting plaque height and GSM. Among women with <1 year since FMP, Factor 1 
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was significantly associated with greater maximum plaque height independent of CVD risk 
factors and medication use. Among women with ≥1 year since their FMP, Factor 1 was 
associated with lower minimum GSM. This association was only borderline statistically 
significant after adjustment for traditional CVD risk factors.  
We chose to utilize an EFA approach due to the fact that many of the inflammatory and 
coagulation biomarkers associated with atherosclerotic CVD are interdependent, and this method 
addresses concerns of multicollinearity that arise when conducting regression analysis involving 
multiple biomarkers. EFA allows for the identification of underlying construct (factors) among a 
group of items with no a priori hypothesis (i.e. biologically naïve). Therefore, the results of our 
EFA provide insight into the underlying relationships among the circulating markers included in 
this analysis, and suggest that these markers may contribute jointly to the pathologic processes 
involved in carotid plaque development in midlife women. The factors that emerged from the 
present EFA are similar to those identified via the EFA described in the previous chapter 
(Section 3.4). In both analyses, Factor 1 was composed of CRP, IL-6, and fibrinogen, likely 
representing a non-specific inflammatory process. CRP is synthesized by hepatocytes in response 
to IL-6 secretion by macrophages and T cells, and both are generalized markers of inflammation 
with prognostic value in regards to CVD (39, 43, 208, 209). Similar to CRP, fibrinogen is an 
acute phase reactant synthesized by hepatocytes in response to inflammation that contributes to 
platelet aggregation and is converted to fibrin in order to form blood clots (214, 230). Elevated 
fibrinogen has been associated with risk of CHD and stroke (210, 230). As was the case in the 
previously described EFA, the second factor identified in this analysis is a factor likely 
representing a thrombogenic process within the vasculature. In the present sample, Factor 2 was 
composed of D-dimer and vwAntigen. D-dimer is a fibrin degradation product that is present in 
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the blood once the coagulation cascade has been activated (231, 232). It has been associated with 
increased risk of CHD in prospective studies (58, 233). vwAntigen is a marker of VWF, a 
protein produced by endothelial cells and megakaryocytes that facilitates clotting by binding to 
platelets and various proteins involved in the coagulation cascade (80).  
When considering the composition of the factors in combination with our regression 
analyses, these results suggest that increased inflammatory and coagulation burden are predictive 
of greater atherosclerotic plaque burden among women within the normal BMI range, but not 
among women overweight or obese. Adipose tissue is pro-inflammatory and secretes cytokines, 
such as IL-6, that have atherogenic effects (262, 263), and the relationship between BMI and 
CRP in women is well-established (264, 265). Therefore, the existing low-grade inflammation 
inflammatory burden affecting women with greater adiposity may have contributed to the lack of 
effect seen among women who were overweight or obese.  
We also found that inflammatory burden was related to greater plaque height among 
women with <1 year since their FMP, and lower GSM among women with ≥1 years since their 
FMP. These results support our hypothesis that circulating inflammatory burden is associated 
with B-mode ultrasound-derived carotid plaque characteristics that are indicative of plaques that 
may be more prone to rupture; however, suggest that these relationships are moderated by time 
since FMP. One possible explanation of the relationship between inflammatory burden and 
plaque height in perimenopausal women (<1 years since FMP) is that one hallmark of the 
menopausal transition is a dramatic drop in estrogen levels, and evidence suggests that some 
estrogens have anti-inflammatory effects within the vasculature (266, 267). Plaque height is a 
dynamic characteristic of plaque that capable of experiencing changes over a relatively short 
period of time. Rollefstad et al. have previously reported significant regression in plaque height 
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following the initiation of statin therapy, and found this effect was not dependent upon a 
reduction in LDL-cholesterol (252). An abrupt decrease in levels of anti-inflammatory hormones 
following the onset of the menopausal transition may influence remodeling or expansion of 
atherosclerotic plaque; however, this is entirely speculation. The observed relationship between 
Factor 1 and minimum GSM among postmenopausal women is also important in that a woman’s 
risk of experiencing a cardiovascular event increases following menopause (241) and plaques 
with low echogenicity have been associated with increased risk of both stroke and coronary 
events in longitudinal studies (137, 138, 148). Low GSM plaques are more likely to contain 
plaque components associated with instability such as lipid rich necrotic core (LRNC), 
vascularity, and intraplaque hemorrhage (133-136). These results highlight the importance of 
inflammatory burden as a marker of cardiovascular risk in midlife women, and suggest that the 
inflammatory burden may increase a woman’s cardiovascular risk by negatively influencing 
characteristics and components of atherosclerotic plaque.  
Our study has several limitations worth noting. First, this cross-sectional analysis does 
not allow us to make conclusions regarding the causal influence of inflammatory and coagulation 
on plaque burden and characteristics. Since we used B-mode ultrasound to characterize plaques, 
we cannot directly identify specific components of plaque that are associated with inflammatory 
and coagulation burden, but utilized surrogate markers of these components. Additionally, our 
sample excluded smokers and those with any clinical CVD. The relationships found in our study 
may be different among smokers and those with CVD, who likely have higher inflammatory 
burden compared to our sample. Similarly, our participants were predominately white (76%), 
with very few Asian and Hispanic participants; therefore, these results are not generalizable 
across racial and ethnic groups.  
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In summary, we found that a higher circulating inflammatory and coagulation burden was 
associated with greater burden of atherosclerotic plaque in the carotid arteries of midlife women 
within the normal range of BMI who were clinically free of CVD. Additionally, we found that 
higher circulating inflammatory burden was associated with greater maximum plaque height 
among perimenopausal women and lower minimum GSM among postmenopausal women. 
These findings highlight important associations between circulating inflammatory and 
coagulation burden with measures of atherosclerotic plaque burden and characteristics, and 
suggest that increased inflammatory and coagulation burden may serve as mechanisms 
contributing to the progression and complication of atherosclerotic plaque in midlife women.  
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4.6 TABLES AND FIGURES 
Table 4.1 Characteristics of the 277 MS Heart Participants in Sample 
Characteristic MS Heart Sample 
Age 55 (52-57) 
Race (non-white) 67 (24%) 
Education 
      High School/Some College 112 (40%) 
     College Graduate 80 (29%) 
     Post-Graduate 85 (31%) 
Hard to Pay for Basics 
      Not Hard 194 (71%) 
     Somewhat Hard 64 (23%) 
     Very Hard 17 (6%) 
Self-Rated Health 
      Excellent or Very Good 200 (72%) 
     Good or Fair 77 (28%) 
Menopausal Status 
      Perimenopausal 44 (16%) 
     Post-Menopausal 233 (84%) 
Physiologic Hot Flashes 137 (49%) 
Years Since FMP 3.3 (1.7-6.3) 
BMI (kg/m2) 27 (24-32) 
SBP (mmHg) 118 (110-128) 
DBP (mmHg) 69 (63-76) 
Diabetes 7 (3%) 
HOMA-IR 2.1 (1.6-3.0) 
HDL (mg/dL) 63 (53-72) 
LDL (mg/dL) 129 (108-152) 
Triglycerides (mg/dL) 94 (71-128) 
SHBG (nmol/L) 83.1 (53.9-131.2) 
PSQI 5 (4-7) 
Berlin Sleep High Risk 76 (27%) 
Average HF-HRV 199.3 (108.0-358.7) 
CRP (mg/L) 1.28 (0.64-2.90) 
IL-6 (pg/mL) 1.44 (0.95-2.23) 
Fibrinogen (mg/mL) 337.70 (292.40-381.70) 
D-dimer (ug/mL) 233.87 (171.71-367.47) 
vWF Antigen (IU/dL) 1.35 (1.01-1.68) 
FVII (mg/dL) 1.26 (1.09-1.45) 
Medication Use
     Anti-hypertensive 43 (16%) 
     Anti-Diabetic 8 (3%) 
     Lipid-Lowering  38 (14%) 
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Table 4-1 Continued 
     Sleep  14 (5%) 
     Anti-coagulation  28 (10%) 
     Beta Agonists 13 (5%) 
     Anti-Inflammatory 52 (19%) 
Outcomes 
      Plaque Present 127 (46%) 
     Total Number of Plaques 0 (0-1) 
Among Those with Plaque: 
      Total Plaque Area (mm2) 16.8 (9.8-26.2) 
     Maximum Height (mm) 2.0 (1.7-2.5) 
     Minimum GSM  49.3 (39.8-67.4) 
     Presence of Calcification 40 (32%) 
a Median (25th-75th percentile) provided for all continuous variables and 
b N (%) provided for categorical variables 
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Table 4.2 Biomarker FActor Loadings based on Exploratory Factor Analysis 
Biomarker Factor 1 Factor 2 
CRP (mg/L) 0.99 - 
IL-6 (pg/mL) 0.47 - 
Fibrinogen (mg/mL) 0.38 - 
D-dimer (ug/mL) - 0.39
vWF Antigen (IU/dL) - 0.63
FVII (mg/dL) - - 
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Table 4.3 Characteristics of the Study Sample by Tertiles of Biomarker Factors 
Factor 1 (CRP, IL-6, Fibrinogen) Factor 2 (D-Dimer, VW Factor Antigen) 
Characteristic T1 T2 T3 p T1 T2 T3 p 
Age 54 (50-57) 55 (53-58) 55 (52-57) 0.08 54 (50-56) 55 (52-58) 55 (52-57) 0.07 
Race (non-white) 20 (22%) 17 (18%) 30 (33%) 0.08 20 (22%) 17 (18%) 30 (33%) 0.08 
Education 0.34 0.17 
     HS/Some College 30 (33%) 38 (41%) 44 (47%) 31 (34%) 35 (38%) 46 (49%) 
     College Graduate 32 (35%) 26 (28%) 22 (23%) 25 (27%) 30 (33%) 25 (27%) 
     Post-Graduate 29 (32%) 28 (31%) 28 (30%) 35 (38%) 27 (29%) 23 (24%) 
Hard to Pay for Basics 0.01 0.42 
     Not Hard 69 (76%) 70 (77%) 55 (58%) 65 (72%) 67 (74%) 62 (67%) 
Somewhat/Very Hard 22 (24%) 20 (23%) 39 (42%) 26 (28%) 24 (26%) 31 (34%) 
Self-Rated Health <0.01 0.01 
Excellent/Very Good 16 (18%) 20 (22%) 41 (44%) 15 (16%) 28 (30%) 34 (36%) 
Good or Fair 75 (82%) 72 (78%) 53 (56%) 76 (84%) 64 (70%) 60 (64%) 
Post-menopausal 72 (79%) 78 (85%) 83 (88%) 0.23 72 (79%) 81 (88%) 80 (85%) 0.24 
Years Since FMP 3.0 (1.5-6.0) 3.4 (1.7-6.5) 3.3 (1.4-6.8) 0.63 3.2 (1.4-6.0) 3.1 (1.7-7.7) 3.4 (1.7-5.8) 0.40 
BMI (kg/m2) 24 (21-27) 27 (24-29) 33 (29-36) <0.01 25 (22-28) 28 (25-32) 31 (25-35) <0.01 
SBP (mmHg) 113 (105-122) 118 (109-125) 125 (115-113) <0.01 113 (106-122) 120 (110-131) 120 (113-131) <0.01 
DBP (mmHg) 68 (62-76) 68 (62-74) 72 (65-79) 0.03 67 (61-75) 70 (64-77) 69.8 (64.0-78.0) 0.03 
Diabetes 1 (1%) 1 (1%) 5 (5%) 0.11 1 (1%) 1 (1%) 5 (5%) 0.11 
HOMA 1.9 (1.5-2.3) 2.0 (1.6-2.7) 2.8 (1.9-4.2) <0.01 1.8 (1.5-2.3) 2.3 (1.7-3.1) 2.4 (1.8-3.6) <0.01 
HDL-c (mg/dL) 67 (56-76) 63 (54-73) 58 (47-69) <0.01 64 (55-76) 61 (55-70) 61 (49-71) 0.04 
LDL-c (mg/dL) 123 (102-148) 129 (109-148) 134 (111-158) 0.13 122 (100-144) 137 (111-155) 126 (107-152) 0.04 
Triglycerides(mg/dL) 82 (68-109) 98 (71-129) 102 (76-150) <0.01 86 (67-120) 93 (75-130) 100 (76-135) 0.17 
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a Median (IQR) provided for all continuous variables, Kruskal Wallis test used to compare groups. 
b N (%) provided for categorical variables, Chi-square test used to compare groups 
SHBG (nmol/L) 107.8 (65.4-155.1) 89.9 (58.7-132.4) 62.7 (45.6-93.0) <0.01 90.0 (53.1-138.0) 85.2 (52.2.-126.3) 78.4 (54.3-131.2) 0.79 
PSQI 5 (3-7) 5 (3-7) 5 (4-7) 0.70 5 (3-7) 5 (4-7) 5 (4-7) 0.69 
Berlin High Risk 17 (19%) 27 (29%) 46 (49%) <0.01 17 (19%) 26 (28%) 47 (50%) <0.01 
Average HF-HRV 219.1 (132.9-367.2) 191.1 (112.9-346.0) 171.6 (88.0-361.2) 0.41 193.6 (122.0-351.9) 191.1 (99.6-388.4) 210.5 (99.6-354.9) 0.99 
Medication Use 
Anti-hypertensive 8 (9%) 13 (14%) 22 (23%) 0.02 9 (9%) 11 (12%) 23 (23%) 0.01 
Anti-diabetic 2 (2%) 1 (1%) 5 (5%) 0.20 1 (1%) 1 (1%) 6 (6%) 0.05 
Lipid-lowering 10 (11%) 12 (13%) 16 (17%) 0.43 10 (11%) 11 (12%) 17 (18%) 0.31 
Sleep 7 (8%) 5 (5%) 2 (2%) 0.22 8 (9%) 4 (4%) 2 (2%) 0.11 
Beta-agonist 3 (3%) 4 (4%) 6 (6%) 0.60 4 (4%) 6 (7%) 3 (3%) 0.55 
Anti-coagulation 11 (12%) 5 (5%) 12 (13%) 0.19 10 (11%) 8 (8%) 10 (11%) 0.86 
Any Anti-
inflammatory 13 (14%) 22 (24%) 17 (18%) 0.24 15 (16%) 21 (23%) 16 (17%) 0.47 
CRP (mg/L) 0.5 (0.3-0.6) 1.3 (1.1-1.5) 4.2 (2.9-6.2) <0.01 0.8 (0.4-1.4) 1.4 (0.6-2.8) 2.5 (1.2-4.6) <0.01 
IL6 (pg/mL) 0.9 (0.7-1.2) 1.3 (0.9-1.8) 2.0 (1.5-2.7) <0.01 0.9 (0.7-1.3) 1.3 (1.1-1.8) 2.1 (1.6-2.8) <0.01 
Fibrinogen (mg/mL) 300.5 (260.9-333.7) 330.2 (286.2-358.0) 
374.4 (334.8-
421.7) <0.01 288.0 (251.5-328.5) 334.6 (299.6-372.2) 
373.8 (335.9-
429.6) <0.01 
D-dimer (ng/mL) 204.2 (145.3-331.6) 225.7 (162.8-305.4) 
293.3 (217.5-
466.7) <0.01 172.4 (128.8-246.7) 224.4 (173.6-311.5) 
367.1 (232.4-
510.7) <0.01 
Factor VII (IU/dL) 1.2 (1.0-1.4) 1.2 (1.1-1.4) 1.3 (1.1-1.5) <0.01 1.2 (1.1-1.4) 1.3 (1.1-1.4) 1.3 (1.1-1.5) <0.01 
vWF Antigen(mg/dL) 1.2 (1.0-1.5) 1.2 (1.0-1.5) 1.4 (1.1-1.8) 0.01 0.9 (0.8-1.1) 1.4 (1.2-1.5) 1.7 (1.4-2.1) <0.01 
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Table 4.4 Characteristics of the Study Sample by Tertiles of Factor Scores 
Factor 1 (CRP, IL-6, Fibrinogen) Factor 2 (D-Dimer, VW Factor Antigen) 
 
T1 T2 T3 p-value T1 T2 T3 p-value
Plaque 
Present 37 (40%) 46 (36%) 44 (35%) 0.44 39 (31%) 40 (32%) 48 (38%) 0.46 
Total # of 
Plaques 0 (0-1) 0 (0-1) 0 (0-2) 0.49 0 (0-1) 0 (0-1) 0 (0-2) 0.22 
Total Plaque 
Area (mm2) 14.4 (8.3-24.2) 16.8 (9.8-26.9) 19.7 (11.1-30.3) 0.42 14.6 (8.8-22.5) 16.8 (9.9-24.8) 20.6 (11.1-30.8) 0.27 
Minimum 
GSM 56.5 (36.9-77.6) 47.8 (37.7-65.2) 53.6 (39.8-67.4) 0.83 49.3 (42.7-66.7) 49.3 (34.8-73.9) 50.0 (39.8-63.8) 0.94 
Maximum  
Height (mm) 1.9 (1.7-2.3) 2.0 (1.6-2.6) 2.1 (1.8-2.4) 0.66 1.8 (1.7-2.4) 2.0 (1.7-2.5) 2.1 (1.6-2.6) 0.84 
Calcification 9 (10%) 15 (16%) 16 (17%) 0.32 7 (8%) 18 (20%) 15 (16%) 0.06 
a Median (IQR) provided for all continuous variables, Kruskal-Wallis test used to compare groups. 
b N (%) provided for categorical variables, Chi-square test used to compare groups 
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Table 4.5 Associations of Biomarker Factor Tertiles with Measures of Plaque Presence and Burden 
a Beta estimates (se)  and odds ratios (95% CI) provided where appropriate. 
b Model 2 adjusts for age, race, and self-rated health  
c Model 3 adjusts for Model 2 + BMI, SBP, HDL, SHBG, HOMA, PSQI, physiologic hot flashes, and self-rated health 
d Model 4 adjusts for Model 2 + medication use (antihypertensive, lipid-lowering, diabetes, sleep)
Biomarker 
Factor 
Tertile 
PLAQUE PRESENCE TOTAL # OF PLAQUES TOTAL PLAQUE AREA 
Model 2 Model 3 Model 4 Model 2 Model 3 Model 4 Model 2 Model 3 Model 4 
Factor 1: CRP, IL-6, Fibrinogen 
Tertile 1 (ref) 
Tertile 2  
1.28 
(0.70,2.33) 
1.56 
(0.81,3.03) 
1.26 
(0.68,2.33) 
1.12 
(0.78,1.62) 
1.03 
(0.69,1.56) 
1.02 
(0.70,1.49) -2.20 (4.47) -4.27 (4.38) -0.67 (4.49)
Tertile 3 
1.10 
(0.57,2.13) 
1.85 
(0.81,4.30) 
0.94 
(0.47,1.90) 
1.23 
(0.84,1.81) 
1.16 
(0.68,1.86) 
1.32 
(0.88,1.99) 1.18 (4.79) -4.70 (5.30) 1.03 (4.80)
Factor 2:  D-dimer, vWF Antigen 
Tertile 1 (ref) 
  
Tertile 2  
0.97 
(0.53,1.78) 
0.82 
(0.42,1.60) 
0.94 
(0.50,1.76) 
1.23 
(0.84,1.80) 
1.07 
(0.73,1.56) 
1.20 
(0.81,1.77) -1.15 (4.63) -1.34 (4.39) -1.24 (4.57)
Tertile 3 
1.27 
(0.66,2.43) 
1.14 
(0.56,2.34) 
1.08 
(0.54,2.12) 
1.37 
(0.94,2.00) 
1.16 
(0.78,1.74) 
1.07 
 (0.72,1.77) 1.93 (4.63) -0.32 (4.49) 0.05 (4.71)
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a OR point estimates with corresponding 95% CIs depicted 
b Model adjusts for age, race, self-rated health, BMI, SBP, HDL, SHBG, HOMA, PSQI, 
physiologic hot flashes, and self-rated health 
c ‡ Indicates significance at the α=0.05 level
d BMI<25 n=98; BMI ≥25 n=206 
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Figure 4.1 Associations of the Highest Biomarker Factor Tertiles with Total Number of Carotid Plaques 
‡
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a Beta estimates with corresponding SE estimates depicted 
b Model 2 adjusts for age, race, and self-rated health 
c Model 3 adjusts for Model 2 + BMI, SBP, HDL, SHBG, HOMA, PSQI, physiologic hot 
flashes, and self-rated health 
d Model 4 adjusts for Model 2 + medication use (antihypertensive, lipid-lowering, diabetes, 
sleep) 
e ‡ Indicates significance at the α=0.05 level 
f BMI<25 n=98; BMI ≥25 n=206
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Table 4.6 Associations of Biomarker Factor Tertiles with Carotid Plaque Characteristics 
 
a Beta estimates (se) and odds ratios (95% CI)  provided where appropriate.  
b Model 2 adjusts for age, race, and self-rated health  
c Model 3 adjusts for Model 2 + BMI, SBP, HDL, SHBG, HOMA, PSQI, physiologic hot flashes, and self-rated health 
d Model 4 adjusts for Model 2 + medication use (antihypertensive, lipid-lowering, diabetes, sleep)
Biomarker 
Factor 
Tertile 
MINIMUM GSM MAXIMUM HEIGHT PRESENCE OF CALCIFICATION 
Model 2 Model 3 Model 4 Model 2 Model 3 Model 4 Model 2 Model 3 Model 4 
        Factor 1: CRP, IL-6, Fibrinogen       
Tertile 1 
(ref) 
         
Tertile 2  -2.51 (5.38) -4.26 (5.46) -2.74 (5.48) 0.07 (0.15) -0.00 (0.16) 0.09 (0.15) 
1.31 
(0.46,3.76) 
0.80 
(0.23,2.81) 
1.10 
(0.35,3.44) 
Tertile 3 -5.48 (5.75) -4.90 (6.61) -5.63 (5.87) 0.07 (0.16) 0.06 (0.19) 0.07 (0.17) 
1.84 
(0.60,5.58) 
0.77 
(0.15,3.97) 
2.17 
(0.63,7.49) 
        Factor 2: D-dimer, vWF Antigen 
   Tertile 1 
(ref) 
         
Tertile 2  -0.67 (5.56) -1.07 (5.48) -1.05 (5.58) -0.03 (0.16) -0.03 (0.16) -0.04 (0.16) 
2.77 
(0.9,8.30) 
2.97   
(0.89-9.91) 
3.02 
(0.94,9.68) 
Tertile 3 1.70 (5.57) 0.86 (5.61) 2.69 (5.75) 0.00 (0.16) -0.09 (-0.16) -0.03 (0.16) 
1.49 
(0.49,4.57) 
1.11 
(0.31,4.03) 
1.26 
(0.35,4.51) 
96 
 
 
a Beta estimates with corresponding SE estimates depicted 
b Model 2 adjusts for age, race, and self-rated health 
c Model 3 adjusts for Model 2 + BMI, SBP, HDL, SHBG, HOMA, PSQI, physiologic hot 
flashes, and self-rated health 
d Model 4 adjusts for Model 2 + medication use (antihypertensive, lipid-lowering, diabetes, 
sleep) 
e ‡ Indicates significance at the α=0.05  
f <1 Year since FMP n=56, ≥1Years since FMP n=248 
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a Beta estimates with corresponding SE estimates depicted 
b Model 2 adjusts for age, race, and self-rated health 
c Model 3 adjusts for Model 2 + BMI, SBP, HDL, SHBG, HOMA, PSQI, physiologic hot 
flashes, and self-rated health 
d Model 4 adjusts for Model 2 + medication use (antihypertensive, lipid-lowering, diabetes, 
sleep) 
e ‡ Indicates significance at the α=0.05  
f <1 Year since FMP n=56, ≥1Years since FMP n=248 
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5.1 ABSTRACT 
Introduction: Perceived discrimination is positively associated with cardiovascular risk factors 
and events. However, questions remain regarding the potential mechanisms through which 
perceived discrimination may influence cardiovascular risk and how experiences of 
discrimination may be associated with markers of subclinical CVD including atherosclerotic 
plaque presence, burden, and characteristics.  
Methods: 300 late peri- and postmenopausal women who were free of clinical CVD completed 
the Everyday Discrimination scale and underwent B-mode carotid ultrasound. Associations 
between everyday discrimination (frequency of day-to-day interpersonal mistreatment) and 
measures of carotid plaque presence, burden (total number of plaques, total plaque area), and 
characteristics (maximum height, minimum GSM, and calcification) were evaluated using 
regression analyses adjusting for demographics, as well as CVD and psychosocial risk factors. 
Circulating inflammatory burden was evaluated as a potential mediator of the relationship 
between everyday discrimination and subclinical CVD. 
Results: After adjustment for demographics, CVD and psychosocial risk factors, women who 
experienced high levels of everyday discrimination had maximum plaque height 0.29 mm greater 
(p=0.03) than those who did not experience high levels of discrimination. Circulating 
inflammatory burden was a partial mediator of this relationship (natural indirect effect through 
mediator=1.21 95%CI=1.17, 1.25). Everyday discrimination score and a modified high 
discrimination score were both associated with a greater total number of carotid plaques 
(OR=1.03 95%CI=1.00- 1.07 and OR=1.09 95%CI=1.01-1.07, respectively) in minimally 
adjusted models including age, race, and difficulty paying for basic items; however these 
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relationships were no longer statistically significant after adjustment for CVD and psychosocial 
risk factors.  
Discussion: These results add to the existing evidence that experiences of everyday 
discrimination have negative health effects among women of various racial/ethnic groups, and 
suggest that increased inflammatory burden and greater carotid plaque height may be 
mechanisms through which experiences of discrimination increase women’s cardiovascular risk 
at midlife. 
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5.2 INTRODUCTION 
CVD is the leading cause of death among U.S. women, and self-reported experiences of 
discrimination have been associated with greater risk of incident cardiovascular events and all-
cause mortality across racial and ethnic groups (185, 268). The associations between self-
reported discrimination with lifestyle and risk factors implicated in CVD vary slightly based on 
the population of interest and measure of discrimination, but ultimately, perceived discrimination 
has been associated with smoking (177), preterm birth (269, 270), hypertension (192), poor sleep 
(176), and depression (184) among women. Understanding the relationship between experiences 
of discrimination and CVD in women is important because the evidence suggests that the 
physiologic mechanisms contributing to CVD differ among men and women, and that 
interpersonal stress may elicit a more robust stress response in women compared to men (155, 
271).  
Atherosclerotic plaque in the carotid artery is an important preclinical marker of CVD 
that is associated with increased risk of ischemic stroke (100, 246), CHD (127, 247), and 
cardiovascular mortality (249, 272). In addition to plaque presence, greater burden of plaque in 
the carotid artery is associated with increased risk of stroke (124), MI (125, 126), and MACE 
(120). One study has previously linked everyday discrimination with greater carotid plaque 
burden among African American women; however, this relationship was only marginally 
statistically significant (198).  
B-mode ultrasound, one method of visualizing and quantifying carotid plaque, can also 
be utilized to identify characteristics of plaque that may provide insight regarding the 
vulnerability of plaque to rupture or erode. For example, grey-scale median (GSM), a continuous 
measure of plaque echogenicity, is a surrogate marker of plaque components. Low GSM has 
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been associated with increased lipid content, necrotic core presence, and composite measures of 
plaque instability in histologic studies (134-136), while higher GSM is correlated with greater 
fibrous content among plaques assessed via histology (134). Lower GSM plaque in the carotid 
artery is prospectively associated with increased hazard of MACE among asymptomatic patients 
with carotid artery disease (148). Additionally, the measurement of plaque height and 
calcification may provide further insight into the complexity and potential stability of carotid 
plaques (251, 252). Greater maximum plaque height, or thickness, in the carotid artery is 
longitudinally associated with greater risk of cardiovascular events (253, 254). Calcification of 
plaque in the carotid artery is associated with increased risk of mortality and cardiovascular 
events when comparing individuals with calcified plaque to those with no carotid plaque (150, 
151). However, the increase in calcification observed following the initiation of statin treatment 
suggests that calcification may be a beneficial characteristic of plaque among those with high 
plaque burden (252, 255).   
One of the mechanisms through which perceived discrimination is hypothesized to 
influence cardiovascular risk is increased inflammation (175). Findings from the Study of 
Women’s Health Across the Nation indicate that discrimination is longitudinally associated with 
higher CRP levels in non-obese women of various racial/ethnic groups (273). CRP is a marker of 
systemic inflammation that has been well established as a marker of CVD risk among the general 
population (40), and is has been associated with carotid plaque presence and lower echogenicity 
of carotid plaques (39). Multiple cross-sectional analyses have reported associations between 
perceived discrimination and elevated circulating CRP levels (274, 275), and one study from the 
Multi-Ethnic Study of Atherosclerosis reported an association between perceived discrimination 
and higher levels of IL-6 among women (276).  
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In the present study, we investigate the relationship between perceived discrimination, 
measured by the Everyday Discrimination scale, with measures of carotid plaque presence, 
burden, and characteristics in a sample of midlife women. We hypothesize that greater everyday 
discrimination is associated with greater carotid plaque burden and ultrasound-measured 
characteristics indicative of instability. Furthermore, we hypothesize that the association between 
perceived discrimination and carotid plaque characteristics is mediated by circulating 
inflammatory burden.  
5.3 MATERIALS AND METHODS 
5.3.1 Participants 
The MS Heart Study includes 304 late perimenopausal (2-12 months amenorrhea) and 
postmenopausal (≥12 months amenorrhea) nonsmoking women aged 40-60 years. 
Advertisements, mailings, fliers, referral from local clinics, and online message boards were used 
to recruit participants to the study, which was intended to investigate the relationship between 
menopausal symptoms and CVD risk. By design, half of the participants reported daily hot 
flashes or night sweats within the past three months, while the other half of the participants 
reported no hot flashes or night sweats in the past three months. Women who had previously 
undergone a hysterectomy and/or bilateral oophorectomy, had a history of heart disease, stroke, 
arrhythmia, ovarian/gynecological cancer, pheochromocytoma, pancreatic tumor, kidney failure, 
seizures, Parkinson’s disease, Raynaud phenomenon, previous endarterectomy, endometrial 
ablation, or were currently pregnant, undergoing chemotherapy or dialysis were excluded from 
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the study. Women were also excluded if they had used the following medications in the past 
three months: oral/transdermal estrogen or progesterone, selective estrogen receptor modulators, 
selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, gabapentin, 
insulin, beta blockers, calcium channel blockers, alpha-2 adrenergic agonists, or other 
antiarrhythmic agents.  
Upon inclusion in the study, all participants underwent physical measurements, 
questionnaire completion, blood draw, ambulatory physiologic hot flash monitoring for three 
days, electrocardiogram, actigraphic sleep monitoring, and a carotid artery ultrasound. Four 
women were excluded from the present study due to missing data from the carotid ultrasound 
(poor image quality n=1 and equipment failure n=3). Procedures were approved by the 
University of Pittsburgh Institutional Review Board, and all participants provided written 
informed consent.  
5.3.2 Ultrasound Measurements and Plaque Characterization 
B-mode ultrasound using a Sonoline Antares (Siemens, Malvern, PA) high-resolution 
duplex scanner with a VF10-5 transducer was utilized in order to obtain bilateral carotid images 
Trained sonographers at the University of Pittsburgh Ultrasound Research Laboratory (URL) 
obtained the images according to a standardized protocol. Five carotid segments within both the 
left and right carotid arteries were assessed for plaque: the proximal common carotid artery 
(CCA), the distal common carotid artery (CCA one centimeter distal to the carotid bulb), the 
carotid bulb (where the near and far walls of the common carotid are no longer parallel, 
extending to the flow divider), the internal carotid artery (ICA), and the external carotid artery 
(ECA).  
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Presence of plaque was defined as a focal structure that encroaches into the arterial lumen 
with 50% greater thickness than the surrounding intima-media thickness consistent with the 
Mannheim Consensus Statement (117). Plaque presence and total number of plaques in each 
segment were determined by trained ultrasound readers. Plaque presence was defined as a 
participant having plaque in at least one arterial segment and total number of plaques was 
defined as the sum of all plaques across all of the visualized arterial segments. One trained 
ultrasound reader determined plaque area, height, GSM, and presence of calcification using 
semi-automated Carotid Analyzer software from the Vascular Research Tools 5 Suite (Medical 
Imaging Applications LLC, Coralville, IA). Plaque area for each plaque was calculated by the 
software once the plaque had been traced by the reader and automatically outlined by the 
software. Total plaque area was defined as the sum of plaque area in each of the arterial 
segments. GSM was calculated by the software for each plaque following grey level 
normalization, which aims to minimize the effect of different ultrasound machine gain settings 
during image acquisition. Normalization was performed manually by the ultrasound reader 
selecting a dark area of blood from the lumen and the brightest area of the adventitial layer along 
the anterior or posterior wall. Maximum height was defined as the greatest height value of all 
plaques among participants with plaque present. Minimum GSM was defined as the GSM value 
of the plaque with the lowest GSM for each participant with plaque present. The reader 
subjectively identified calcification after assessing each plaque for highly echogenic areas with 
or without acoustic shadowing. Presence of calcification was defined as a participant having a 
calcified plaque in at least one of the visualized arterial segments.  
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5.3.3 Perceived Discrimination 
A modified version of the Detroit Area Study Everday Discrimination Scale was used to 
assess perceived discrimination among the participants (186). This 10-item instrument utilizes a 
4-point scale (1=never, 2=rarely, 3=sometimes, 4=often) in order to determine the frequency of 
interpersonal maltreatment in the previous 12 months. Examples of items included in the 
Everday Discrimination scale include “You are treated with less respect than other people”, 
“People act as if they think you are not smart”, and “You receive poorer service than other 
people in restaurants or stores. The Everyday Discrimination scale has high levels of internal 
consistency (186, 277), and is validated across racial and ethnic groups (187).  
Responses for each item were summed in order to determine the total Everyday 
Discrimination score (range 0-40) for each participant. We also calculated a high discrimination 
score (range 0-10) where responses of “never” and “rarely” were scored as a zero and responses 
of “sometimes” and “often” were scored as a one. In order to compare participants who reported 
high interpersonal mistreatment compared to those who did not, we categorized individuals who 
responded to at least one item on the Everyday Discrimination scale with “sometimes” or “often” 
into a high perceived discrimination group. This approach has been used previously (191) and 
was suggested by Williams et al (186). Women who reported that they experience high 
discrimination (answered “sometimes” or “often” to at least one item) were asked to identify the 
characteristic to which they attributed this interpersonal maltreatment. Options included race, 
ethnicity, gender, age, income level, language, physical appearance, sexual orientation, and 
other. 
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5.3.4 Inflammatory and Coagulation Biomarkers 
High sensitivity CRP was measured using a high-sensitivity reagent set (Beckman 
Coulter, Brea, CA, USA), and IL-6 was measured using an R&D Systems high sensitivity 
enzyme-linked immunosorbant assay (Minneapolis, MN, USA). Fibrinogen was measured using 
a modified Clauss method and Siemens Multifibren U reagent (Newark, DE, USA), and 
quantitative D-dimer was measured using a Diagnostica Stago’s Asserachrom assay (Asnieres 
sur Seine, France). Standard clotting methods via a Siemens Innovin thromboplastin reagent with 
Factor VII-deficient plasma (HRF, Raleigh, NC, USA) was used in order to measure Factor VII 
clotting activity, and vWF Antigen was measured using Diagnostica Stago’s STA-Liatest reagent 
(Asnieres sure Seine, France).  
5.3.5 Covariates and Additional Measures 
Participants self-reported their race/ethnicity, education level, shift work, medical and 
psychiatric history, health behaviors, and medication use (BP lowering, lipid lowering, diabetes, 
depression, anxiety, sleep) via questionnaire.  Height and weight were measured using a fixed 
stadiometer and a balance beam scale in order to calculate BMI. Resting BP was measured using 
a Dinamap device after a seated 10-minute rest period, and the final BP was defined as the 
average of the second and third BP reading. Menopausal status was categorized as 
perimenopausal (>2-<12 months amenorrhea) or postmenopausal (≥12 months amenorrhea) 
(256). Depressive symptoms were assessed by the Center for Epidemiologic Studies Depression 
scale (278) and anxiety symptoms were assessed via the State Trait Anxiety Inventory (279). 
Participants also completed the Pittsburgh Sleep Quality Index (PSQI) in order assess sleep 
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quality (257) and the Berlin Sleep Questionnaire in order to assess sleep apnea symptoms such as 
snoring (258). Glucose, total cholesterol, triglycerides, and HDL, were assessed enzymatically 
(Vital Diagnostics, Lincoln, RI) following a blood draw that took place after a 12-hour fast, and 
LDL was calculated using the Friedewald equation (221). Insulin level was measured by 
radioimmunoassay, and HOMA was calculated. Physiologic hot flashes were monitored over a 
24-hour period using sternal skin conductance monitoring (260, 261). A VU-AMS monitor (VU 
University Amsterdam, Netherlands) was used to sample skin conductance from the sternum at 1 
Hz from two Ag-Ag Cl electrodes. Participants were categorized into groups consisting of those 
who experienced physiologic hot flashes over the 24-hour monitoring period and those who did 
not. 
5.3.6 Statistical Analysis 
Chi-square and Kruskal-Wallis tests were used to compare differences in categorical and 
continuous participant characteristics, respectively, among those who indicated that they 
experienced high levels of discrimination (at least one “sometimes” or “often” response) 
compared to those who did not. Logistic regression was used to assess the associations between 
the various measures of perceived discrimination with plaque presence and presence of 
calcification. Zero-inflated Poisson regression was used to measure the associations between the 
measures of perceived discrimination with total number of plaques. Among those with plaque, 
linear regression was used to determine association between perceived discrimination with total 
plaque area, maximum plaque height, and minimum GSM. Minimally adjusted models (Model 
2) included age, race, and difficulty paying for basics, and more fully adjusted models (Model 3) 
included age, race, difficulty paying for basics, BMI, SBP, PSQI, depressive symptoms, 
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menopausal status, physiologic hot flashes, social support, lipid-lowering medication use, and 
diabetes medication. Interactions were tested for using cross product terms in models and Wald 
tests were used to indicate statistical significance. 
The potential mediating effect of circulating inflammatory burden on significant 
relationships between perceived discrimination and plaque characteristics was tested using a 
causal inference approach. This approach, which is based on inverse probability weighting, 
allows for the estimation of natural direct and natural indirect effects, and works best when both 
the exposure and outcome are dichotomous (280). Inflammatory burden was modeled as a score 
corresponding to an inflammatory factor consisting of CRP, IL-6, and fibrinogen that emerged 
from an EFA of circulating biomarkers previously conducted in the MS Heart sample, and 
outcomes were dichotomized. The proportion of the relationship explained by the mediator was 
calculated using the following formula: Proportion Explained = (Total Effect – Direct Effect) / 
Total Effect. All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC).  
5.4 RESULTS 
Women who reported experiencing high levels of perceived discrimination (high everyday 
discrimination score ≥1) had poorer self-rated health, greater difficulty paying for basic items, 
higher PSQI scores, and were more likely to be considered high-risk by the Berlin Sleep 
Questionnaire (Table 5.1). They also had higher total CESD scores, state and trait anxiety scores, 
and less social support compared to those who did not indicate that they experienced high levels 
of discrimination. Among non-white women, the most common characteristic to which the 
women attributed their experiences of discrimination was race (42%) followed by “other’ (27%) 
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and physical appearance (12%) (Table 5.2). Among white women the most common attribution 
responses were “other” (53%), age (18%), and income level (12%).  
Nearly half of the women had at least one carotid plaque (46%), and among those with 
plaque 33% had plaque that was calcified (Table 5.3). In univariate analyses, there were no 
differences in plaque presence, total number of plaques, minimum GSM, and presence of 
calcification between women who reported experiencing high levels of everyday discrimination 
compared to those who reported low levels of everyday discrimination. However, women who 
reported experiencing high levels of everyday discrimination had greater total plaque area (22.41 
mm2 vs. 15.50 mm2, p=0.02) and greater maximum plaque height (2.24 mm vs. 1.87 mm, 
p=<0.01) compared to women who reportedly experienced low levels of discrimination.  
In the multiple regression analysis, everyday discrimination score was associated with a 
greater total number of plaques such that a 1-point increase in the score was associated with a 
1.03 times higher number of plaques after adjustment for age, race, and difficulty paying for 
basic items (95% CI = 1.00-1.07) (Table 5.4). Similarly, a 1-point greater high discrimination 
score was associated with a 1.09 times higher number of plaques after adjustment for age, race, 
and difficulty paying for basics (95% CI=1.01-1.07). These associations were no longer 
statistically significant after adjustment for traditional CVD risk factors and psychosocial 
measures. No associations were observed between any of the discrimination measures with 
plaque presence and total plaque area before or after adjustment for covariates.  
Women who indicated that they experienced high discrimination had on average a 
maximum plaque height 0.30 mm greater (p=0.01) than those who indicated that they did not 
regularly experience discrimination (Table 5.5, Figure 5.1). This association was maintained 
even after adjustment for covariates. Greater high discrimination scores were similarly associated 
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with greater plaque height (B=0.07 p=0.02), but this relationship was attenuated to borderline 
significance after adjustment for CVD risk factors and psychosocial measures; particularly 
depression and social support. These results were not moderated by race, physiologic hot flashes, 
or menopausal statues.  
The results of the mediation analysis indicated that women who experienced high 
Everyday Discrimination were 2.75 times more likely to have a plaque in the highest tertile of 
plaque height, and that inflammatory burden (factor composed of CRP, IL-6, and fibrinogen) 
explained 31% of the relationship between high discrimination and plaque height (Figure 5.2). 
The natural direct effect of high discrimination on plaque height was 1.52 (95% CI=1.49-1.58) 
while the natural indirect effect through the inflammatory mediator was 1.21 (95% CI=1.17-
1.25). 
5.5 DISCUSSION 
In a sample of midlife women free of clinical CVD we found that high perceived everyday 
discrimination was independently associated with greater maximum plaque height in the carotid 
artery. Furthermore, the observed relationship between everyday discrimination and plaque 
height was mediated by greater circulating inflammatory burden. These associations were 
independent of demographics, as well as traditional CVD and psychosocial risk factors. In 
minimally adjusted models, we also observed a significant association between everyday 
discrimination and a greater total number of carotid plaques; however, this relationship was not 
statistically significant after adjustment for CVD and psychosocial risk factors. We did not find 
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any significant associations between everyday discrimination with carotid plaque presence, area, 
minimum GSM, or calcification.  
To our knowledge, this is the first study to evaluate the associations between perceived 
discrimination and characteristics of atherosclerotic plaque. One prior study aimed at examining 
the associations between various forms of psychosocial stress and carotid IMT reported a 
marginal relationship between everyday discrimination attributed to race and higher plaque 
score; however, these analyses were exploratory and limited in sample size (198). The Everyday 
Discrimination Scale utilized in the present study is intended to measure relatively minor day-to-
day experiences of interpersonal maltreatment. These experiences are considered to be ongoing, 
and more common in daily life than more major experiences of discrimination (e.g. being denied 
a job or loan) (183). Furthermore, evidence suggests that responses to the Everyday 
Discrimination Scale remain stable overtime (196). Our study adds to the growing literature 
supporting an association between these relatively minor, ongoing experiences of discrimination 
to negative effects on the cardiovascular health of women.  
Additionally, maximum carotid plaque height (or thickness) has been identified as an 
important predictor of risk of a cardiovascular event in MESA, and the Northern Manhattan 
Study (253, 254). Plaque height is a dynamic characteristic that may experience significant 
changes over a relatively short period of time; for example, following initiation of statin therapy 
(252). In our analyses, the effect of high perceived everyday discrimination on maximum carotid 
plaque height was nearly 1.5 times that of lipid-lowering medication  (B=0.30 p<0.01 vs. B=-
0.18, p=0.13, respectively), and our results were consistent even after exclusion of women using 
lipid-lowering drugs. These findings highlight an important relationship between everyday 
discrimination and subclinical CVD, and add to the growing evidence of the negative impact that 
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day-to-day discriminatory experience may have on cardiovascular health of women across 
racial/ethnic groups.   
The associations between everyday discrimination and carotid atherosclerosis in our 
sample did not differ by race. These findings are consistent with prior studies reporting no 
differences in the associations between everyday discrimination and CVD risk factors among 
women of various racial/ethnic groups. For example Lewis et al. have previously reported no 
differences in the associations between everyday discrimination and poor sleep (176) as well as 
greater visceral adiposity (189) among multi-ethnic SWAN participants. Furthermore, in their 
2009 review of the health effects of perceived discrimination, Pascoe and Richman report that 
the evidence suggests perceived discrimination has similar negative health consequences 
regardless of racial/ethnic background (175). 
We did not find any significant associations between everyday discrimination with 
plaque presence, total area, minimum GSM, and calcification. However, it is worth mentioning 
that while the results were not statistically significant, the effects of high everyday discrimination 
on total plaque area and minimum GSM among women with carotid plaque trended in the 
expected direction (greater total plaque area and lower minimum GSM). When considered in 
conjunction with the observed relationship between everyday discrimination and plaque height, 
these results suggest that everyday discrimination may be a better predictor of carotid plaque 
progression than initial lesion development midlife women.  
We also conducted a mediation analysis in order to determine whether the association 
between high everyday discrimination and greater plaque height is mediated by circulating 
inflammatory burden. Inflammatory burden, operationalized as factors score (composed of CRP, 
IL-6, and fibrinogen) based on a factor derived from a previous EFA in our study sample, was 
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identified as partial mediator that accounts for an estimated 31% of the relationship between 
everyday discrimination and maximum plaque height. These results are consistent with past 
studies linking everyday discrimination to higher circulating inflammation (273), and our 
previous findings in the MS Heart sample linking higher inflammatory burden to greater carotid 
plaque thickness. However, to our knowledge, this study is the first to identify inflammation as a 
mediator of the relationship between everyday discrimination and plaque height. Our results 
suggest that inflammatory burden may be a mechanism through which everyday discrimination 
influences plaque height; however, additional longitudinal studies are required in order to 
confirm this relationship.  
This study has several limitations. First, the cross-sectional nature of the study does not 
allow us to draw conclusions about temporality or causality of the identified relationships. Our 
sample includes few Asian and Hispanic women, and therefore, the results may not be 
generalizable to those groups. Approximately 40% (n=120) of participants in the sample reported 
experiencing high discrimination and were asked to elaborate regarding the suspected reason to 
which they attributed their experiences of discrimination, and the majority of women chose to 
respond “other” and fill in a written response. Therefore, there were not enough women who 
attributed their experience of discrimination to the provided reasons (e.g. race, age, physical 
appearance) for us to determine if specific types of discrimination were more important in terms 
of subclinical CVD compared to others. Lastly, minimum GSM of plaque is only a surrogate 
marker of plaque components, so we are unable to draw any conclusions regarding the potential 
associations between everyday discrimination and specific components of carotid plaque that 
may put women at risk of a cardiovascular event.   
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Strengths of our analysis include that participants were asked to complete questionnaires 
for a variety of psychosocial risk factors (e.g. depression, anxiety, and social support) that are 
strongly associated with discrimination; therefore we were able to adjust for psychosocial risk 
factors in our analyses. Our results remained significant after taking these measures, as well as 
other traditional CVD risk factors, into account. Additionally, we conducted sensitivity analyses 
excluding those on lipid-lowering medications since they are known to affect plaque height, and 
our results remained consistent after excluding those participants.  
In sum, we report that high levels of everyday discrimination are associated with greater 
maximum carotid plaque height among midlife women without clinical CVD after adjustment 
for demographics, as well as traditional CVD and psychosocial risk factors. Furthermore, we 
found that circulating inflammatory burden is a mediator of the relationship between high 
everyday discrimination and maximum carotid plaque height. These results suggest that 
increased inflammatory burden and greater atherosclerotic plaque height may be mechanisms 
through which experiences of discrimination increase women’s cardiovascular risk at midlife. 
Future studies are warranted to evaluate the temporality of these relationships, and identify 
strategies to that may be useful in combatting both experiences of everyday discrimination and 
the associated negative health consequences in women.  
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5.6 TABLES AND FIGURES 
Table 5.1Characteristics of MS Heart Study Sample by Perceived Discrimination Severity 
Characteristic 
Low Perceived 
Discrimination  
(n=184) 
High Perceived 
Discrimination  
(n=120) p-value  
Age 55 (52-57) 55 (51-57) 0.8146 
Race (white) 130 (73%) 86 (72%) 0.8251 
Education     0.4199 
     High School/Some College 79 (43%) 50 (42%)   
     College Graduate 57 (31%) 31 (26%)   
     Post-Graduate 48 (26%) 39 (33%)   
Hard to Pay for Basics     0.0001 
     Not Hard 139 (77%) 67 (56%)   
     Somewhat Hard 38 (21%) 40 (33%)   
     Very Hard 4 (2%) 13 (11%)   
BMI (kg/m2) 27 (24-33) 28 (26-33) 0.3834 
Self-Rated Health     0.0009 
     Excellent/Very Good 143 (78%) 72 (60%)   
     Good/Fair 41 (22%) 48 (40%)   
Post-menopausal 154 (84%) 101 (84%) 0.9131 
Physiologic Hot Flashes 90 (49%) 62 (52%) 0.6388 
SBP (mmHg) 118 (110-128) 119 (111-128) 0.4364 
DBP (mmHg) 69 (63-77) 71 (64-76) 0.4817 
Diabetes 5 (3%) 3 (3%) 0.9694 
HOMA 2.1 (1.7-3.2) 2.4 (1.7-3.1) 0.4647 
HDL (mg/dL) 61 (53-71) 64 (51-73) 0.8293 
LDL  (mg/dL) 125 (106-151) 136 (109-156) 0.2144 
Triglycerides (mg/dL) 96 (73-127) 97 (70-139) 0.7777 
CESD Total 3 (1-8) 9 (5-15) <0.0001 
State Anxiety Score 28 (24-35) 34 (26-39) <0.0001 
Trait Anxiety Score 29 (25-36) 37 (31-44) <0.0001 
PTSD 2 (1%) 5 (4%) 0.1171 
Overall Support 44 (38-46) 38 (33-44) <0.0001 
PSQI 5 (3-6) 6 (4-8) 0.0002 
Berlin Sleep High Risk 40 (22%) 47 (40%) 0.0010 
CRP (mg/L) 1.2 (0.6-2.8) 1.4 (0.7-3.1) 0.3029 
IL6 (pg/L) 1.4 (1.0-2.2) 1.5 (0.9-2.2) 0.7598 
Fibrinogen (mg/mL) 335.1 (290.1-382.3) 342.6 (294.2-379.5) 0.9771 
D-dimer (ng/mL) 244.5 (171.2-380.4) 227.2 (173.5-331.8) 0.7136 
Factor VII (mg/dL) 1.2 (1.1-1.4) 1.3 (1.1-1.5) 0.5164 
vwAntigen (IU/dL) 1.4 (1.1-1.7) 1.2 (0.9-1.7) 0.0462 
Medication Use: 
        Anti-hypertensive 31 (17%) 17 (14%) 0.5309 
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Table 5.1 Continued    
     Lipid-lowering 29 (16%) 10 (8%) 0.0584 
     Anti-coagulant 19 (10%) 11 (9%) 0.7404 
     Anti-diabetic 7 (4%) 3 (3%) 0.7451 
     Anti-depressant 4 (2%) 2 (2%) 1.0000 
     Anti-anxiety 4 (2%) 1 (1%) 0.6515 
     Any Anti-inflammatory 30 (16%) 24 (20%) 0.4099 
     Sleep 8 (4%) 6 (5%) 0.7909 
 
a Median (IQR) provided for all continuous variables, Kruskal-Wallis test used to compare 
groups.  
b N (%) provided for categorical variables, Chi-square test used to compare groups 
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Table 5.2Attributions of Discrimination Among Those Who Perceive that They are Frequently 
Discriminated Against 
Discrimination Attribution 
Overall 
(n=120)  
Non-White 
(n=34) 
White 
(n=86)  
Race 14 (12%) 14 (42%) 0 
Ethnicity 0 0 0 
Gender 7 (6%) 1 (3%) 6 (7%) 
Age 17 (15%) 2 (6%) 15 (18%) 
Income Level 13 (12%) 3 (9%) 10 (12%) 
Language 0 0 0 
Physical Appearance 12 (10%) 4 (12%) 8 (10%) 
Sexual Orientation 0 0 0 
Other 53 (46%) 9 (27%) 44 (53%) 
No Response 4 (3%) 1 (2%) 3 (3%) 
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Table 5.3 Plaque Outcomes Among all MS Heart Participant and Comparison of Plaque Outcomes 
between Those with Low and High Perceived Discrimination 
 
Outcome 
All Participants 
(n=304) 
Low Perceived 
Discrimination 
(n=184) 
High Perceived 
Discrimination  
(n=120) p-value 
Any Plaque 139 (46%) 88 (48%) 51 (43%) 0.3181 
Total # of Plaques 0 (0-1) 0 (0-1) 0 (0-1) 0.5598 
Total Plaque Area (mm3) 17.49 (9.87-36.51) 15.50 (9.18-24.70) 22.41 (14.05-31.32) 0.0249 
Minimum GSM 53. 61 (39.82-67.39) 53.61 (39.82-67.40) 53.61 (41.29-67.38) 0.9712 
Max Height (mm) 2.02 (1.71-2.46) 1.87 (1.63-2.26) 2.24 (1.90-2.78) 0.0016 
Calcification 46 (33%) 31 (25%) 15 (29%) 0.4825 
 
a Median (IQR) provided for all continuous variables, Kruskal-Wallis test used to compare those 
with and without high levels of perceived discrimination.  
b N (%) provided for categorical variables, Chi-square test used to compare those with and 
without high levels of perceived discrimination
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Table 5.4 Associations of Perceived Discrimination with Measures of Plaque Presence and Burden 
 
Plaque Presence Total Number of Plaques Total Plaque Area 
Measure of 
Discrimination Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 
Everyday 
Discrimination 
Score 
0.98  
(0.93,1.03) 
0.98  
(0.93,1.03) 
0.98  
(0.92,1.04) 
1.03  
(1.00,1.06)* 
1.03  
(1.00,1.07)‡ 
1.02  
(0.99,1.06) 0.40 (0.41) 0.47 (0.45) 0.19 (0.44) 
 
High 
Discrimination 
Score 
0.97 
 (0.85,1.09) 
0.97  
(0.85,1.10) 
0.96  
(0.82,1.12) 
1.06  
(0.99,1.14) 
1.09  
(1.01,1.18)‡ 
1.08  
(0.99,1.17) 1.69 (1.02) 2.19 (1.10) 1.74 (1.08) 
 
High 
Discrimination 
(yes/no) 
1.27 
 (0.80,2.01) 
0.80  
(0.49,1.30) 
0.75  
(0.44,1.28) 
1.17  
(0.87,1.57) 
1.17  
(0.87,1.58) 
1.08  
(0.79,1.49) 5.34 (3.73) 5.58 (3.96) 3.56 (3.94) 
 
 
a Beta estimates (se) and odds ratios (95% CI) provided where appropriate.  
b ‡ indicates significant at α=.05 level. * indicates borderline significance (0.05< p <0.06) 
a Model 1: Unadjusted 
b Model 2 Covariates: Age, race, difficulty paying for basics 
c Model 3 Covariates: Age, race, difficulty paying for basics, SBP, BMI, diabetes medication, lipid-lowering medication, physiologic 
hot flashes, menopausal status, depressive symptoms, social support, and PSQI 
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Table 5.5 Associations of Perceived Discrimination with Plaque Characteristics 
 
Minimum GSM Maximum Height Presence of Calcification 
Measure of 
Discrimination Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 
Everyday 
Discrimination 
Score -0.49 (0.45) -0.67 (0.50) -0.58 (0.51) 0.01 (0.01) 0.00 (0.01) 0.00 (0.01) 
0.92  
(0.85,1.01) 
0.92  
(0.84,1.12) 
0.91  
(0.81,1.01) 
 
High 
Discrimination 
Score -1.27 (1.12) -1.79 (1.25) -2.02 (1.27) 0.07 (0.03)‡ 0.08 (0.03)‡ 0.07 (0.04)* 
0.80  
(0.62,1.02) 
0.83  
(0.63,1.09) 
0.81  
(0.60,1.10) 
 
High 
Discrimination 
(yes/no) -0.85 (4.14) -2.39 (4.49) -4.40 (0.35) 0.31 (0.11)‡ 0.30 (0.12)‡ 0.29 (0.14)‡ 
1.31  
(0.62,2.75) 
0.85  
(0.36,2.01) 
0.87  
(0.34,2.24) 
 
a Beta estimates (se) and odds ratios (95% CI) provided where appropriate.  
b ‡ indicates significant at α=.05 level. * indicates borderline significance (0.05< p <0.06) 
c Model 1: Unadjusted 
d Model 2 Covariates: Age, race, difficulty paying for basics 
e Model 3 Covariates: Age, race, difficulty paying for basics, SBP, BMI, diabetes medication, lipid-lowering medication, physiologic 
hot flashes, menopausal status, depressive symptoms, social support, and PSQI
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 a Beta estimates (se) provided  
b ‡ indicates significant at α=.05 level. * indicates borderline significance (0.05< p <0.06) 
c Model 2 Covariates: Age, race, difficulty paying for basics 
d Model 3 Covariates: Age, race, difficulty paying for basics, SBP, BMI, diabetes medication, 
lipid-lowering medication, physiologic hot flashes, menopausal status, depressive symptoms, 
social support, and PSQI 
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Figure 5.1Associations of Perceived Discrimination with Maximum Plaque Height 
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Figure 5.2 Inflammatory Burden as a Mediator of the Relationship between 
Perceived Discrimination and Maximum Plaque Height 
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6.0  DISSERTATION CONCLUSIONS 
6.1 MAJOR FINDINGS 
The analyses presented in this dissertation contribute significantly to the existing body of 
knowledge regarding the associations of markers of inflammatory and coagulation burden with 
subclinical atherosclerosis in the carotid and femoral arteries. Using exploratory factor analyses, 
this work consistently identified two distinct factors, one factor representing chronic low-grade 
inflammation and another factor representing coagulation in two different populations: 
community-living older adults and midlife women. The identified factors were differentially 
associated with B-mode ultrasound-derived measures of plaque presence, burden, and 
characteristics within the carotid and femoral arteries of the aforementioned populations.   
In the community-living, healthy older adults of the San Diego Population Study, we 
found that the factor representing coagulation burden, comprised of PTX-3 and D-dimer, was 
initially associated with measures of femoral plaque presence and burden in unadjusted 
regression models, while the inflammatory factor, comprised of CRP, IL-6, and fibrinogen, was 
not significantly associated with any measures of plaque presence burden or characteristics 
before or after adjustment for covariates. The association of the factor representing coagulation 
with plaque presence and burden in these unadjusted models suggests that coagulation burden 
may be more important in regards to femoral plaque development than inflammatory burden. 
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This conclusion is supported by the evidence documenting a hypercoagulable state among those 
with PAD (281), and that higher coagulation burden is a predictor of PAD severity (43). It is also 
possible that the coagulation markers measured in this analysis were superior markers of 
atherosclerotic processes in this population compared to the inflammatory markers measured in 
this study. 
Among midlife women in the MS Heart Study, we again identified two distinct factors 
following an exploratory factor analysis: an inflammatory factor comprised of CRP, IL-6, and 
fibrinogen as well as a coagulation factor comprised of D-dimer and vwAntigen. There were no 
significant associations between either factor with the measures of plaque presence, burden, or 
characteristics among the entire MS Heart sample. However, we identified relationships between 
the inflammatory and coagulation factors with measures of carotid plaque burden that were 
moderated by BMI. Among women with BMI < 25kg/m2, higher levels of the factor representing 
chronic low-grade inflammation were associated with greater total plaque area after adjustment 
for covariates, and  the factor representing coagulation burden was associated with a greater total 
number of plaques after adjustment for covariates. There were no significant associations 
between either factor with the measures of plaque burden among women with BMI ≥25kg/m2. 
The lack of association between either factor and plaque burden among women with BMI > 25 
kg/m2 may be due to a combination of factors including that women with higher BMI may have 
been already exposed to some levels of chronic low-grade inflammation due to greater adiposity 
Additionally, the strict exclusionary criteria of the MS Heart study did not allow for the inclusion 
of women with numerous chronic diseases including history of heart disease, stroke, arrhythmia, 
and several cancers. Therefore, it is possible that the MS Heart participants considered 
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overweight or obese may be uniquely healthier compared to overweight or obese women in the 
general population.  
Additionally, we identified several relationships between the inflammatory and 
coagulation factors with carotid plaque characteristics that were moderated by time since FMP in 
this sample. Among women with less than one year since their FMP, higher inflammatory 
burden was associated with greater maximum plaque height and higher coagulation burden was 
associated with lower maximum plaque height after adjustment for covariates. Among women 
with more than one year since their FMP, higher inflammatory burden was associated with lower 
minimum GSM after covariate adjustment. These results support our hypothesis that greater 
inflammatory burden is associated with carotid plaque characteristics indicative of potentially 
less stable plaque; however, they also indicate that the relationship between circulating 
inflammatory burden and plaque characteristics may differ throughout the menopausal transition. 
A previous analysis conducted in the Study of Women’s Health Across the Nation (SWAN), 
found that lipid changes are differentially related to subclinical measures of atherosclerosis in the 
years leading up to, immediately preceding, and immediately following the FMP (282). Similar 
to the results of our analysis, SWAN investigators found that greater increases in low-density 
lipoprotein cholesterol were related to greater carotid plaque burden within the year following 
the FMP, but not at other time periods throughout the menopausal transition. Some evidence 
suggests that estrogens exert anti-inflammatory effects throughout the vasculature, and one 
possible explanation for these findings is that a dramatic drop in estrogen levels following the 
FMP may result in greater vascular inflammation leading to changes in plaque (266, 267); 
however, further longitudinal studies are necessary to investigate these hypothesized 
relationships.  
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In the third analysis of this dissertation, we found a significant association between high 
levels of perceived everyday discrimination and greater maximum carotid plaque height among 
midlife women in the MS Heart study. As we hypothesized, this relationship was partially 
mediated by inflammatory burden, specifically the inflammatory factor representing chronic 
low-grade inflammatory burden that we identified via exploratory factor analysis. These findings 
are consistent with the growing evidence that chronic low-grade inflammation is a mechanism 
through which psychosocial stress may influence CVD (152, 153). The associations observed in 
our analyses were consistent across racial groups. And while no statistically significant 
associations were observed between the inflammatory and coagulation markers with the other 
plaque characteristics (i.e. minimum GSM and calcification) considered in this analysis 
following covariate adjustment, these relationships trended in the hypothesized direction.  
When considering the findings of these three analyses together, our results suggest that 
that B-mode ultrasound may have more value in the characterization of plaques that are more 
likely to be considered complex or high risk such as those in the carotid arterial bed compared to 
the femoral arterial bed (89). However, it is important to note that one of the major limitations of 
the femoral artery plaque analysis is that the femoral images of the SDPS were not originally 
collected with the intention of identifying and characterizing plaque. Therefore, the quality of 
some femoral plaque images may have limited our ability to accurately determine plaque 
characteristics. Furthermore, the relatively low burden of femoral artery atherosclerosis in the 
older adults of the San Diego Population Study may have limited our ability to identify 
relationships between circulating inflammatory and coagulation burden with femoral plaque 
measures. It is possible that the results of this analysis may differ had these relationships been 
examined within a more high risk population with more advanced femoral atherosclerosis.  
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Overall, the results of these analyses also suggest that higher coagulation burden may be 
more important in terms of the development of femoral atherosclerosis compared to 
inflammatory burden, while inflammatory burden seems to be of greater importance in regards to 
carotid plaque development and progression. These conclusions are supported by previously 
mentioned evidence documenting a hypercoagulable state among those with PAD (281), and that 
higher coagulation burden is a predictor of PAD symptoms and severity (43). Similarly, these 
findings are supported by several studies reporting a consistent relationship between 
inflammatory markers and the initiation and progression of atherosclerotic plaque in the carotid 
artery (39, 44, 45, 56). 
Due to the fact that these analyses examined several plaque outcomes (i.e. plaque 
presence, total number of plaques, total plaque area, minimum GSM, maximum plaque height, 
and calcification) but only found consistent relationships between our predictors and maximum 
plaque height, it is important to consider what differences may exist between maximum plaque 
height and the various other plaque measures. Maximum plaque height, sometimes referred to as 
plaque thickness, is a dynamic characteristic of plaque that is capable of experiencing changes 
over a relatively short period of time. Rollefstad et al. have previously reported significant 
regression of plaque height in the 18 months following the initiation of statin therapy (252). 
Furthermore, this effect was not dependent upon a reduction in LDL-cholesterol, and the authors 
suggest that it may be primarily driven by the anti-inflammatory effects of statins. It is possible 
that maximum plaque height is more susceptible to the influence of inflammatory factors 
compared to the other plaque measures and characteristics we collected. Furthermore, plaque 
height may simply have the capacity to change over a shorter period of time compared to the 
other measures we examined such as GSM and calcification.  Additionally, when considering 
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these findings it is important to note that maximum plaque height has been identified as an 
important predictor of risk of a cardiovascular event in MESA, and the Northern Manhattan 
Study (253, 254), and shows additive value in the prediction of vascular events and CHD beyond 
cIMT and coronary artery calcium, respectively (283, 284).  
This dissertation has several important limitations. As mentioned above, the samples 
studied in this dissertation are unique and this may have influenced the results of our analyses. 
The SDPS is a relatively healthy aging cohort with a low burden of femoral artery 
atherosclerosis. The MS Heart study is comprised of non-smoking women without existing CVD 
and had strict criteria excluding women with a history of heart disease, stroke, arrhythmia, and 
the use of numerous medications. Therefore, it is possible that our analyses are not generalizable, 
and may differ if conducted in individuals more representative of the general population. Neither 
of the studies utilized in this dissertation were designed with the intention of studying the effects 
of inflammation cardiovascular disease. Therefore, limited measures of inflammatory and 
coagulation biomarkers were available for these analysis. It is possible that there are other 
markers of inflammation and coagulation that are more important in terms of plaque 
development and progression than those that were included in these analyses. Additionally, 
circulating levels of inflammatory and coagulation markers may be difficult to accurately 
ascertain from a single time point as was done in this study due to the instability of biomarkers 
and their variability over time. Due to the cross-sectional nature of these analyses, our ability to 
draw conclusions about the temporality of the relationships that we observed is limited. Although 
B-mode ultrasound is a relatively inexpensive and feasible method of visualizing plaque in the 
superficial arteries, and is particularly useful in large epidemiologic studies, it is limited in 
regards to plaque characterization. The fact that this dissertation utilized B-mode ultrasound 
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images for plaque characterization does not allow us to draw conclusions regarding the potential 
relationships between inflammatory and coagulation burden with specific components of 
atherosclerotic plaque.  
6.2 PUBLIC HEALTH SIGNIFICANCE & FUTURE DIRECTIONS 
Globally, CVD is the leading cause of death, and the majority of cardiovascular morbidity and 
mortality is due to atherosclerotic CVD (5). The rupture or erosion of atherosclerotic plaque is 
the primary cause of MI and ischemic stroke, which affect an estimated 1.4 million U.S. adults 
annually. Inflammation is one of the driving forces contributing to atherosclerosis (26), and the 
associations between greater levels of circulating inflammatory markers with CVD are well-
established (208, 216, 285). Recently, the results of a randomized controlled trial published in 
the New England Journal of Medicine reported that adults who received treatment with a 
monoclonal antibody aimed at reducing inflammation had a significantly lower hazard of 
myocardial infarction, nonfatal stroke, or cardiovascular death over 48 months of follow-up 
(286). However, the mechanisms through which inflammation may influence cardiovascular risk 
are not entirely understood. Studying the relationships between inflammation and measures of 
atherosclerotic plaque in subclinical stages can help shed light on the mechanisms through which 
inflammation may influence one’s cardiovascular risk. 
Midlife is a dynamic time for women’s cardiovascular health during which 
atherosclerosis is accelerated  (239, 240) and risk of a cardiovascular event increases (242). This 
dissertation reports that higher circulating inflammatory burden are associated with carotid 
plaque characteristics that are indicative of potentially less stable plaques in midlife women, and 
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suggests that inflammatory burden may contribute to CVD risk in midlife women by negatively 
influencing carotid plaque characteristics. However, additional longitudinal analyses in 
generalizable samples of midlife women are needed in order to ascertain whether chronic low-
grade inflammation influences carotid plaque characteristics and subsequently increases 
cardiovascular risk. Moreover, we found that the associations between higher inflammatory 
burden and plaque characteristics indicative of instability were not consistent across the 
menopausal transition. These results suggest that inflammation may influence to atherosclerosis 
differently throughout menopause, and warrant further longitudinal analyses in order to 
determine how inflammation may contribute to changes in atherosclerotic plaque characteristics 
and components at different times throughout the menopausal transition. 
Among women, psychosocial stress is a well-established risk factor associated with 
increased CVD risk. The influence of chronic psychosocial stress on atherosclerosis is 
particularly important to study among women because women manifest CVD different than men, 
and inflammation, which is hypothesized to be a mechanism through which stress influence 
CVD risk, is a better predictor of CHD among women (155). Additionally, psychosocial stress 
may contribute to the vast racial/ethnic disparities in CVD observed in the U.S. (183). 
This dissertation examined the associations between one form of psychosocial stress, 
everyday discrimination, with measures of carotid plaque presence, burden, and characteristics 
among midlife women. As described in previous sections, the literature regarding the 
associations between everyday discrimination and subclinical CVD is limited to few subclinical 
cardiovascular outcomes, and the results are mixed. This dissertation is the first study to report 
on associations between everyday discrimination with carotid plaque burden and characteristics. 
We found that high levels of everyday discrimination were significantly associated with higher 
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maximum carotid plaque height among midlife women. Furthermore, we report that 
inflammatory burden is a partial mediator of this relationship. These results were consistent 
among women of different racial groups. Plaque height is a dynamic plaque characteristic that 
has the ability to change over a relatively short period of time (252), and has additive value to 
cIMT and traditional risk factors in regards to predicting risk of a CVD event (287). Our results 
support the hypothesis that inflammation is a mechanism linking everyday discrimination and 
cardiovascular disease among women; however, longitudinal analyses conducted among 
generalizable groups of women are needed in order to determine temporality and causality. 
Lastly, these results are consistent with the existing literature suggesting that perceived everyday 
discrimination is associated with subclinical CVD among women of various racial and ethnic 
groups, and demonstrate the need for additional studies aimed at mitigating the negative health 
effects of discrimination among women.  
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APPENDIX: SUPPLEMENTARY DATA 
 
 
Figure 6.1 Relationship between Factor 1 and BMI among those with BMI <25 kg/m2 
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Figure 6.2 Relationship between Factor 1 and BMI among those with BMI ≥25 kg/m2 
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